The ChIP-seq and RNA seq raw data employed in this study are deposited at the NCBI Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>), under accession nos. GSE138429 and GSE144835.

Introduction {#sec001}
============

Meiosis is a specialized developmental program dedicated to the production of genetically unique haploid gametes \[[@pgen.1008905.ref001]\]. The production of haploid gametes is made possible by several meiosis-specific events, chief among them the event of homologous chromosome segregation during the first meiotic chromosome segregation event (*i*.*e*. meiosis I). Faithful segregation of homologs requires that initially unconnected homologous chromosomes are physically linked prior to segregation. Homolog linkage is achieved by interhomologue-directed crossover repair of programmed DNA double-strand breaks (DSBs) prior to meiosis I (*i*.*e*. during meiotic G2/prophase). DSBs are introduced by Spo11, a topoisomerase-like protein, which acts in conjunction with several accessory factors \[[@pgen.1008905.ref002]\]. DSB formation happens in the context of a specialized, meiosis-specific chromosome architecture \[[@pgen.1008905.ref003]\] \[[@pgen.1008905.ref004]\]. Several protein factors, such as Hop1 and Red1 in budding yeast, (whose functional and structural homologs are HORMAD1/2 and SYCP2/3 in mammalians, respectively) \[[@pgen.1008905.ref005]\] \[[@pgen.1008905.ref006]\] \[[@pgen.1008905.ref007]\] drive the assembly of chromosomes into linear arrays of chromatin loops that emanate from a proteinaceous structure termed the meiotic chromosome axis. Red1 and Hop1 co-localize with the meiotic cohesin complex (containing the meiosis-specific Rec8 kleisin subunit instead of the canonical Scc1) to form the molecular foundation of this typical meiotic 'axis-loop' chromosome structure \[[@pgen.1008905.ref008], [@pgen.1008905.ref009]\]. A zipper-like assembly called the synaptonemal complex (SC) polymerizes between synapsing homologous chromosomes \[[@pgen.1008905.ref010]\], concomitantly with, and dependent on ongoing crossover repair of meiotic DSBs \[[@pgen.1008905.ref011], [@pgen.1008905.ref012]\]. In budding yeast, the Zip1 protein is an integral component of the SC, which is assembled onto the axial components of the loop-axis architecture \[[@pgen.1008905.ref013], [@pgen.1008905.ref014]\]. The SC likely acts as a signaling conduit that coordinates DSB activity and repair template preferences with chromosome synapsis \[[@pgen.1008905.ref015]--[@pgen.1008905.ref017]\]. A major role for the SC lies in directing the chromosomal recruitment of the hexameric AAA+ enzyme Pch2 \[[@pgen.1008905.ref015], [@pgen.1008905.ref018], [@pgen.1008905.ref019]\], an important mediator of DSB activity, repair, and checkpoint function (reviewed in \[[@pgen.1008905.ref020]\]). The molecular mechanisms of Pch2 recruitment to synapsed chromosomes remain poorly understood. In *zip1Δ* cells, Pch2 cannot be recruited to meiotic chromosomes (except to the nucleolus/rDNA; see below) \[[@pgen.1008905.ref018]\]. However, this is unlikely via a direct molecular interaction. First, a specific Zip1-mutant (*zip1-4LA*) uncouples SC formation from Pch2 recruitment \[[@pgen.1008905.ref015], [@pgen.1008905.ref021]\]. Second, in cells lacking the histone H3 methyltransferase Dot1, Pch2 can be recruited to unsynapsed chromosomes in *zip1Δ* cells \[[@pgen.1008905.ref022], [@pgen.1008905.ref023]\]. Third, a recent report has linked topoisomerase II (Top2) function to Pch2 association with synapsed chromosomes \[[@pgen.1008905.ref024]\], hinting at a connection between chromosome topology and Pch2 recruitment.

Functionally, the recruitment of Pch2 to synapsed chromosome is connected to the abundance of Hop1 on chromosomes \[[@pgen.1008905.ref015], [@pgen.1008905.ref018], [@pgen.1008905.ref025]\]. The current model is that Pch2 recruitment to SC-forming chromosomal regions allows it to use its ATPase activity to dislodge Hop1 from synapsed regions \[[@pgen.1008905.ref026]--[@pgen.1008905.ref028]\], causing a coupling of SC formation to a reduction in DSB activity, interhomologue repair bias and checkpoint function \[[@pgen.1008905.ref015], [@pgen.1008905.ref020]\]. It is not clear whether Pch2 recruitment alone is sufficient to drive altered Hop1 dynamics upon synapsis, and additional aspects of chromosome metabolism, such as structural changes and post-translational modifications of axis factors \[[@pgen.1008905.ref024], [@pgen.1008905.ref029]\], have been implicated in crosstalk between Pch2 and Hop1.

In addition to its recruitment to euchromatic regions, Pch2 is recruited to the nucleolus, where it is involved in protecting specific regions of the ribosomal (r)DNA array (and rDNA-flanking euchromatic regions) against Spo11-directed DSB activity \[[@pgen.1008905.ref018], [@pgen.1008905.ref030]\]. The nucleolus is devoid of SC polymerization (and thus of Zip1), and nucleolar recruitment of Pch2 is dependent on Sir2 (a histone deacetylase) and Orc1 (a component of the Origin Recognition Complex (ORC)) \[[@pgen.1008905.ref018], [@pgen.1008905.ref030]\]. Strikingly, with the exception of Zip1, all factors that direct Pch2 recruitment (whether within the rDNA, or within euchromatin) are involved in chromatin function, be it modification (Dot1 and Sir2), binding (Orc1, via its bromo-adjacent homology (BAH) domain) or metabolism (Topoisomerase II). Together, these observations predict an intimate interplay between chromatin and Pch2 binding.

Inspired by this, and with the aim of increasing our understanding of Pch2 function on meiotic chromosomes, we generated a comprehensive map of Pch2 chromosomal association during meiotic G2/prophase. This analysis revealed specific binding sites of Pch2 across the genome. Within euchromatin, these sites map to regions of RNA Polymerase II (RNAPII)-driven transcriptional activity (*i*.*e*. a subset of active genes), and recruitment of Pch2 depended on active RNAPII-driven transcription. Interestingly, the Pch2 binding patterns identified here are distinct from meiotic axis enrichment sites (as defined by Red1, Hop1 and Rec8). Orc1 (and also other ORC subunits) are enriched at Pch2 binding sites, whereas no Pch2 can be found associated with origins of replication, which are the canonical binding sites of ORC \[[@pgen.1008905.ref031]\]. Intriguingly, Orc1 inactivation triggers loss of Pch2 binding at active, euchromatic genes, demonstrating a connection between Pch2 and Orc1 that extends beyond their previously described shared rDNA-associated functions \[[@pgen.1008905.ref030]\]. Although active transcription and Orc1 are equally present in meiotic and mitotic cells, we further show that ectopic expression of Pch2 in vegetatively growing cells is not sufficient to allow recruitment of Pch2 to the identified binding sites within actively transcribed genes. This suggests meiosis-specific requirements that license Pch2 recruitment. In agreement with this, we find that Zip1 is required for the recruitment of Pch2 to the identified transcription-associated binding regions.

Surprisingly, we find that interfering with the pool of Pch2 that associates with active RNAPII transcription does not lead to effects on the chromosomal association of Hop1, despite triggering a significant loss of Pch2 from meiotic chromosomes. This finding could indicate a more complex interplay between chromosome synapsis and Pch2 chromosomal recruitment and function than currently anticipated. We thus uncover characteristics and dependencies for Pch2 recruitment to meiotic chromosomes, and reveal a link between Pch2, SC formation, chromatin and active transcription.

Results {#sec002}
=======

We aimed to generate a detailed genome-wide mapping of the chromosomal localization pattern of Pch2, using chromatin immunoprecipitation followed by deep sequencing (ChIP-seq). For this, we employed an NH2-terminal 3xFLAG-tagged wild type version of Pch2 ([Fig 1A and 1B](#pgen.1008905.g001){ref-type="fig"}). This allele creates a functional protein: 3xFLAG-Pch2 was able to interact with Orc1 \[[@pgen.1008905.ref030]\], and suppresses the synthetic spore viability defects of *rad17Δ pch2Δ* cells \[[@pgen.1008905.ref032], [@pgen.1008905.ref033]\] ([S1A and S1B Fig](#pgen.1008905.s002){ref-type="supplementary-material"}). We also used a mutant allele harboring an E\>Q substitution at position 399 within the AAA+ Walker-B motif (*pch2-E399Q*) ([Fig 1A and 1B](#pgen.1008905.g001){ref-type="fig"}). This mutant is expected to impair ATP hydrolysis, and equivalent mutations have been used to stabilize interactions between AAA+ proteins and clients and/or adaptors \[[@pgen.1008905.ref034]\]. We anticipated that Pch2-E399Q would exhibit increased association to chromosomal regions as compared to its wild type counterpart, which could aid in revealing details regarding Pch2 recruitment and/or function.

![Genome-wide analysis of Pch2 chromosome association.\
A. Schematic of Pch2 domain organization. B. Western blot analysis of expression of Zip1 (upper panel) and 3XFLAG-Pch2 and 3XFLAG-Pch2-E399Q (lower panel) in *ndt80Δ* cells during meiotic G2/prophase at 4 hours after induction into the meiotic program. Pgk1 was used as a loading control. C. Genome browser view representative images (RPKM; see also [Material and Methods](#sec004){ref-type="sec"}) of ChIP-seq binding patterns for 3XFLAG-Pch2 and 3XFLAG-Pch2-E399Q. Shown is a region of Chromosome *XII* (chromosomal coordinates (kb) are indicated). D. High resolution Genome browser view representative images (RPKM; see also [Material and Methods](#sec004){ref-type="sec"}) of 3XFLAG-Pch2 binding patterns across two selected chromosomal regions (chromosomes *XI* and *IX*). Chromosomal coordinates and gene organization are indicated. E. 3XFLAG-Pch2 and 3XFLAG-Pch2-E399Q ChIP-seq enrichment normalized to inputs (log~2~). Datasets were aligned relative to the indicated positions covering Transcription Start Sites (TSS) and coding regions of 3XFLAG-Pch2 and 3XFLAG-Pch2-E399Q binding genes. F. ChIP-qPCR analysis tiling over the *GAP1/TDH3/PPR1* locus and downstream and upstream of their coding regions in *ndt80Δ* cells during meiotic G2/prophase (4 hours). Positions of the primers are indicated. Primer pairs for *GAP1*: 1) GV3197/G3198, 2) GV3195/GV3196, 3) GV2595/GV2596, 4) GV2599/GV2600; 5) GV3199/GV3200, 6: GV3201/GV3202. Primer pairs for *TDH3*: 1) GV3209/G3210, 2) GV3207/GV3208, 3) GV2591/GV2592, 4) GV2593/GV2594; 5) GV3203/GV3204, 6: GV3205/GV3206. Primer pairs for *PPR1* (negative control): 1) GV3214/G3215, 2) GV3211/GV3212, 3) GV2390/GV2391, 4) GV3216/GV3217; 5) GV3218/GV3219. *MCM2* (GV2392/GV2393) and *GAP1* (GV2595/GV2596) loci were used as a negative and positive control respectively. Error bars represent standard error of the mean of three biologically independent experiments performed in triplicate.](pgen.1008905.g001){#pgen.1008905.g001}

We investigated the progression of meiotic G2/prophase and chose to generate ChIP-seq datasets at 4 hours post-induction since at this time point our cultures showed a mixed population of cells in different phases of meiotic G2/prophase (as judged by SC polymerization status) during which Pch2 is known to play important roles ([S1C Fig](#pgen.1008905.s002){ref-type="supplementary-material"}). Note that the strains that were used to generate ChIP-seq datasets (and the majority of subsequent experiments) were *ndt80Δ* in order to prevent exit from meiotic G2/prophase. We compared ChIP-seq datasets for wild-type and *E399Q* Pch2 (performed in triplicates in both cases) and found that these datasets exhibited highly correlated distributions, both at a genome-wide level and at individual loci [S2A and S2B Fig](#pgen.1008905.s014){ref-type="supplementary-material"} and [S3 Table](#pgen.1008905.s015){ref-type="supplementary-material"} (for number of peaks in different replicas). We plotted the pairwise correlation of normalized reads of shared Pch2 wild type and *E399Q* peaks ([S2C Fig](#pgen.1008905.s003){ref-type="supplementary-material"}). The analyses indicate that the increased signal observed in *E399Q* binding relative to wild type is not originated from additional peaks exclusively detected in the Pch2-*E399Q* dataset (see also below).

We used both alleles (*i*.*e*. wild type and E399Q) for several follow-up experiments (see below). We called the peaks using MACS2 with a p-value of e10^-15^ \[[@pgen.1008905.ref009]\]. We found that \~98% of the peaks localized within the coding sequences (CDS) of a subset of RNAPII-transcribed genes distributed on all 16 budding yeast chromosomes (see [S1 Table](#pgen.1008905.s013){ref-type="supplementary-material"} for a list of Pch2 binding CDS sites and [Fig 1C and 1D](#pgen.1008905.g001){ref-type="fig"} for examples of typical binding patterns across selected chromosomal regions. See also [S1D and S1E Fig](#pgen.1008905.s002){ref-type="supplementary-material"} for additional information and ChIP/input plots). Of note, the described peaks do not comprise those identified within the rDNA array on chromosome *XII* (see below). We did not observe Pch2-association within promoters (*i*.*e*. directly upstream of the transcriptional start sites (TSSs)) of these Pch2-bound genes ([Fig 1D--1F](#pgen.1008905.g001){ref-type="fig"}). Pch2 peaks were evenly distributed throughout CDSs and located downstream of TSSs ([Fig 1E](#pgen.1008905.g001){ref-type="fig"}). Association of Pch2 E399Q is stronger relative to wild-type Pch2, as judged by the differences in normalized read counts ([S2D Fig](#pgen.1008905.s014){ref-type="supplementary-material"} and [S1 Table](#pgen.1008905.s013){ref-type="supplementary-material"}). Based on the biochemical characteristics of AAA+ enzymes, the Pch2-E399Q is expected to exhibit stronger binding to clients and/or adaptors \[[@pgen.1008905.ref034]\], and these increased binding patterns suggest that the observed binding sites represent biochemically meaningful interactions.

In addition to the observed association of Pch2 with RNAPII-transcribed genes, we also found Pch2-binding patterns within the rDNA array. Specifically, we found that Pch2 was associated with the *25S* RNAPI-transcribed locus, whereas we did not detect a significant association with *5S* (RNAPIII-transcribed) locus nor with intergenic regions (*NTS1* or *NTS2*) (data is available on <http://www.ncbi.nlm.nih.gov/geo/>), under accession no. GSE138429). These binding patterns might relate to the observed enrichment and function of Pch2 within the nucleolus \[[@pgen.1008905.ref018], [@pgen.1008905.ref030]\] and therefore warrant future investigation. In this manuscript, we however focus our attention on the Pch2 binding patterns across the non-rDNA, euchromatic part of the genome.

We performed a search for enriched Gene Ontology (GO) terms showing a representation for genes involved in various metabolic processes ([S2 Table](#pgen.1008905.s014){ref-type="supplementary-material"}). In addition to these GO terms, Pch2-association was also enriched within certain sporulation-induced (*i*.*e*. meiosis-specific) genes ([S1 Table](#pgen.1008905.s013){ref-type="supplementary-material"}). We next compared our Pch2 datasets to a genome-wide transcriptome (*i*.*e*. mRNA-seq) dataset that we generated from cells synchronously progressing through meiosis (this dataset was also generated in *ndt80Δ* cells 4 hours post induction of meiosis). We then plotted the normalized RNA-seq counts (TPM, transcripts per million) and assessed the expression levels of Pch2 binding genes following our criteria described in materials and methods. This showed that all genes occupied by Pch2 are transcribed during meiosis ([S11C Fig](#pgen.1008905.s012){ref-type="supplementary-material"}), suggesting that transcription is involved in the recruitment of Pch2 to these CDSs. Processed RNA seq data can be found at <http://www.ncbi.nlm.nih.gov/geo/>), under accession no. GSE144835.

To investigate if transcriptional strength of defined genes was predictive of Pch2 binding, we stratified the transcribed genes from our RNA-seq dataset into high, medium and low expression strength (following previously established procedures \[[@pgen.1008905.ref035]\]), and compared expression strength of Pch2-associated genes with these bins ([S2E Fig](#pgen.1008905.s003){ref-type="supplementary-material"}). This analysis showed that Pch2-associated genes produce average mRNA levels, with a wide distribution. We detected only a weak correlation between the normalized reads score of individual Pch2-binding sites and the expression level of the corresponding CDS (Pearson's correlation, R^2^ = 0.3789, [S2F Fig](#pgen.1008905.s003){ref-type="supplementary-material"}). This indicates that, although Pch2 associates with actively transcribed genes, transcriptional strength *per se* likely plays, if any, only a minor role in dictating Pch2 binding. Underscoring this interpretation is the fact that many highly expressed genes do not show significant Pch2 enrichment peaks.

ChIP analysis can be plagued by artefactual ChIP-enrichments, which are mostly clustered at RNAPIII-transcribed genes, but some of which have also been observed to lie within highly-expressed RNAPII-transcribed genes \[[@pgen.1008905.ref036]\]. We performed several analyses and experiments to exclude artefactual binding effects in our ChIP datasets, which we describe in detail in the Supplementary Data. Most importantly, we *i*) compared our datasets to reported artefactual binding sites \[[@pgen.1008905.ref036]\] and found little overlap ([S3A Fig](#pgen.1008905.s004){ref-type="supplementary-material"}); *ii*) did not detect binding of Pch2 to RNAPIII-transcribed tRNA genes ([S3B Fig](#pgen.1008905.s004){ref-type="supplementary-material"}), contrary to what has been reported for artefactual ChIP-enrichments \[[@pgen.1008905.ref036]\]; and *iii*) found that an inert nuclear protein (3xFLAG-dCas9) did not show binding to a defined Pch2-associated site (as would be expected for artefactual ChIP signals), as tested by ChIP-qPCR ([S3C and S3D Fig](#pgen.1008905.s004){ref-type="supplementary-material"}). Based on these and additional experiments that are described below and in the Supplementary Data, we are confident that our Pch2 datasets inform on physiologically relevant biological behavior.

Based on our ChIP-seq results, we employed ChIP followed by real-time quantitative PCR (ChIP-qPCR) to explore the connection between Pch2 and transcription. We designed oligos that tile over the CDSs and upstream and downstream regions of two Pch2-bound genes: *GAP1* and *TDH3*. *PPR1*, an RNAPII-transcribed gene to which Pch2 showed no association by ChIP-seq was used as a negative control. We confirmed transcriptional activity at *GAP1* and *PPR1* by ChIP analysis of active RNAPII (via ChIP of α−PolII-phospho-Ser5, which is used as a read-out of active engagement of RNAPII during transcription elongation (reviewed in \[[@pgen.1008905.ref037]\]([S2H Fig](#pgen.1008905.s003){ref-type="supplementary-material"})). 3xFLAG-Pch2-*E399Q* associated with the CDSs of both *GAP1* and *TDH3*, whereas no significant association was observed at the *PPR1* locus ([Fig 1F](#pgen.1008905.g001){ref-type="fig"} and [S2G Fig](#pgen.1008905.s003){ref-type="supplementary-material"}, see also [S3 Table](#pgen.1008905.s015){ref-type="supplementary-material"} for a spreadsheet containing, in separate sheets, the underlying numerical data for figure panels containing ChIP-qPCR data). Binding patterns at *GAP1* and *TDH*3 closely mirrored the narrow CDS-specific patterns that we found in our ChIP-seq analysis (for example, compare signals for *GAP1* in [Fig 1D and 1F](#pgen.1008905.g001){ref-type="fig"}). We validated the association of wild-type Pch2 and Pch2-E399Q to two additional selected binding genes (*HOP1* and *SSA1*) by ChIP-qPCR, and we confirmed increased binding of Pch2-E399Q as compared to wild-type Pch2 ([S2I and S2J Fig](#pgen.1008905.s003){ref-type="supplementary-material"}). In addition to its catalytic AAA+ domain, Pch2 also possess a non-catalytic NH2-terminal domain (NTD) ([Fig 1A](#pgen.1008905.g001){ref-type="fig"}) \[[@pgen.1008905.ref020]\]. The NTDs of AAA+ ATPases are required to allow AAA+ proteins to interact with clients and adaptors \[[@pgen.1008905.ref026]\] \[[@pgen.1008905.ref038]\] \[[@pgen.1008905.ref020], [@pgen.1008905.ref034]\]. Removal of the NTD of Pch2 abrogated the association of Pch2 to individual selected genes, indicating that the NTD is required for recruitment of Pch2 to gene bodies ([S2I and S2J Fig](#pgen.1008905.s003){ref-type="supplementary-material"}). In this regard, it is important to note that the expression of Pch2 lacking its NTD (Pch2 243--564) was significantly lower as compared to wild type Pch2 (see also [S4 Table](#pgen.1008905.s016){ref-type="supplementary-material"} for a spreadsheet containing, in separate sheets, selected western blot signals for representative western blot images presented in the manuscript). In addition, it has been reported that the NTD of Pch2 harbors a nuclear localization signal \[[@pgen.1008905.ref039]\]. As such, Pch2 243--564 is likely inefficiently localized to the nucleus \[[@pgen.1008905.ref039]\]. In conclusion, we find that during meiotic G2/prophase, Pch2 associates within the body of a selected group of RNAPII-associated genes, and that recruitment depends on characteristics of AAA+ proteins.

Hop1, a HORMA-domain containing client of Pch2 is a central component of the meiotic axis structure \[[@pgen.1008905.ref008], [@pgen.1008905.ref015], [@pgen.1008905.ref018], [@pgen.1008905.ref025]--[@pgen.1008905.ref028], [@pgen.1008905.ref040]\]. Zip1-dependent SC assembly (which drives Pch2 recruitment \[[@pgen.1008905.ref018]\]), is established on the axial element of the meiotic chromosome structure, and Hop1 and Zip1 are therefore expected to reside in molecular proximity of each other (at and near chromosome axis sites, respectively). As such, one hypothesis is that Pch2 is also enriched at meiotic axis-proximal sites, where it might be acting on its client, Hop1. To investigate whether our ChIP dataset could inform on this idea, we compared the binding patterns of Pch2 to those of axial components (*i*.*e*. Red1, Hop1 and Rec8) with available ChIP-seq datasets \[[@pgen.1008905.ref009]\] ([Fig 2A](#pgen.1008905.g002){ref-type="fig"}). Hop1, Red1 and Rec8 showed highly similar binding patterns \[[@pgen.1008905.ref008]\] \[[@pgen.1008905.ref009]\], but the binding patterns of both wild-type and ATP-hydrolysis deficient Pch2 qualitatively diverged from the patterns of these axial elements: Pch2 patterns did not show the similar frequency along chromosomal regions, and, on genome-wide level, showed little overlap with the binding patterns of meiotic axis-factors ([Fig 2A and 2B](#pgen.1008905.g002){ref-type="fig"} and [S4A and S4B Fig](#pgen.1008905.s005){ref-type="supplementary-material"}). We propose that, within the loop-axis organization of meiotic chromosomes, Pch2 associates with (a selected group of) genes located within loops that are located away from the Hop1-Red1-Rec8-defined axis ([Fig 2C](#pgen.1008905.g002){ref-type="fig"}).

![Pch2 and meiotic axis sites.\
A. Genome browser view representative images (RPKM; see also Material and Methods) of ChIP-seq binding patterns for 3XFLAG-Pch2, Hop1, Red1 and Rec8. Data for Hop1, Red1 and Rec8 are from \[[@pgen.1008905.ref009]\]. Shown is a region of Chromosome *XII* (chromosomal coordinates (kb) are indicated). B. Hierarchically clustered heatmap based on correlation coefficients using from 3XFLAG-Pch2-E399Q ChIP-seq datasets as inputs. Hop1, Red1 and Rec8 ChIP-Seq datasets are from \[[@pgen.1008905.ref009]\]. Spearman's correlation values are indicated. C. Model depicting the proposed localization pattern of Pch2 on loops, within the meiotic chromosome loop-axis structure.](pgen.1008905.g002){#pgen.1008905.g002}

We next investigated the effect of RNAPII transcriptional activity on Pch2 occupancy on meiotic chromosomes. To inhibit RNAPII-dependent transcription, we initially used 1,10-Phenanthroline − a small molecule which has previously been described to inhibit RNAPII-dependent transcription \[[@pgen.1008905.ref041]\]. Meiotic yeast cultures expressing 3XFLAG-Pch2 E399Q were treated with 1,10-Phenanthroline for 1 hour ([S5A Fig](#pgen.1008905.s006){ref-type="supplementary-material"}). Under these conditions, we observed a substantial effect on *GAP1* mRNA levels, in cells treated with 1,10-Phenanthroline, whereas Pch2 protein levels were unaffected ([S5B and S5C Fig](#pgen.1008905.s006){ref-type="supplementary-material"}). Inhibition of global transcription reduced Pch2 association to *GAP1* gene by \~50% compared to the mock-treated control situation ([S5D Fig](#pgen.1008905.s006){ref-type="supplementary-material"}), consistent with a role for transcription in promoting the recruitment/association of Pch2 to regions of active transcription.

To achieve a more complete and specific inhibition of RNAPII, we employed the anchor-away technique \[[@pgen.1008905.ref042]\], which has been used to successfully deplete chromosomal proteins during meiosis \[[@pgen.1008905.ref015], [@pgen.1008905.ref024], [@pgen.1008905.ref043], [@pgen.1008905.ref044]\]. This technique is based on an inducible dimerization system that rapidly depletes nuclear proteins based on ribosomal flux, with the aid of a tagged anchor protein, Rpl13A (Rpl13a-2XFKBP12). Rapamycin induces the formation of a ternary complex with a protein of interest that is tagged with FRB ([F]{.ul}KBP12-[R]{.ul}apamycin [B]{.ul}inding-FRB domain of human mTOR) ([Fig 3A](#pgen.1008905.g003){ref-type="fig"}). Successful anchor-away-based inhibition of RNAPII has been described in vegetative cells \[[@pgen.1008905.ref045]\], and we similarly tagged the largest subunit of *RNAPII (Rpo21)* with the FRB tag ([Fig 3A](#pgen.1008905.g003){ref-type="fig"} and [S5E Fig](#pgen.1008905.s006){ref-type="supplementary-material"}). As expected, *rpo21-FRB* cells exhibited severe growth defects in the presence of rapamycin ([Fig 3B](#pgen.1008905.g003){ref-type="fig"}). Immunofluorescence of meiotic chromosome spreads after exposure with Rapamycin for 30 minutes demonstrated efficient nuclear depletion of Rpo21-FRB during meiosis ([Fig 3C and 3D](#pgen.1008905.g003){ref-type="fig"}). We note that Rpo21 was localized to meiotic chromosomes, in a dotted pattern that did not show strong similarity with Zip1 or Hop1 binding patterns ([Fig 3D](#pgen.1008905.g003){ref-type="fig"} and [S5F Fig](#pgen.1008905.s006){ref-type="supplementary-material"}). We performed ChIP-qPCR analysis, using antibodies against phosphorylated-Serine 5 of Rpo21 in meiotic cells following addition of rapamycin. This approach showed that the relative occupancy of RNAPII within *PPR1* and *GAP1* coding regions was substantially reduced after 30 minutes rapamycin treatment in cells expressing Rpo21-FRB ([Fig 3E](#pgen.1008905.g003){ref-type="fig"}). Taken as a whole, these data demonstrate that RNAPII is depleted from the nucleus under this treatment regimen. Interestingly, ChIP analysis revealed that, whereas the protein levels of Pch2 were unaffected ([Fig 3F](#pgen.1008905.g003){ref-type="fig"}), Pch2 association with *GAP1*, *TDH3* and *SSA1* was substantially reduced in Rpo21-FRB-tagged strains treated with rapamycin for 30 minutes ([Fig 3G](#pgen.1008905.g003){ref-type="fig"}), confirming the fact that Pch2 association to defined chromosomal regions depended on RNAPII transcriptional activity.

![Transcription is required for recruitment of Pch2.\
A. Schematic of the anchor away system and Rpo21 within RNAPII. B. Dilution series of wild type and *rpo21-FRB* anchor away strains, grown on YPD or YPD + rapamycin. C. Schematic of treatment regimens used for anchor away experiments in D-I, and [S5G Fig](#pgen.1008905.s006){ref-type="supplementary-material"}. D. Representative images of immunofluorescence of meiotic chromosome spreads in the *rpo21-FRB* anchor away cells treated with DMSO or rapamycin. Chromosome synapsis was assessed by α-Zip1 staining. E. ChIP-qPCR analysis of active transcription (α−Rpo21-phospho-Ser5) in *rpo21-FRB* anchor away cells treated with DMSO or rapamycin at *PPR1* (primer pairs: GV2390/GV2391) and *GAP1* (primer pairs: GV2597/GV2598). Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. F. Western blot analysis of 3XHA-Pch2 in *rpo21-FRB* anchor away cells treated with DMSO or rapamycin. G. ChIP-qPCR analysis of 3XHA-Pch2 in *rpo21-FRB* anchor away cells treated with DMSO or rapamycin at *PPR1* (negative control) (primer pair: GV2390/GV2391), *GAP1* (primer pair: GV2597/GV2598), *HOP1* (primer pair: GV2607/GV2608), *TDH3* (primer pair: GV2591/GV2592), and *SSA1* (primer pair: GV2587/GV2588). Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. H. Representative images of immunofluorescence of meiotic chromosome spreads in the 3XHA-Pch2 expressing *rpo21-FRB* anchor away cells, treated with DMSO or rapamycin. Chromosome synapsis was assessed by α-Gmc2 staining. White line and asterisk indicate the position of the nucleoli. I. Quantification of non-nucleolar Pch2 intensity per spread nucleus for the immunofluorescences shown in H, treated with DMSO or rapamycin and from the immunofluorescence shown in [S5H Fig](#pgen.1008905.s006){ref-type="supplementary-material"} (*ndt80Δ* and *ndt80Δzip1Δ* cells collected at 4 hours after induction into the meiotic program.) \* indicates a significance of p = 0.01--0.05, Mann-Whitney U test. See [S3 Table](#pgen.1008905.s015){ref-type="supplementary-material"} for exact p-values.](pgen.1008905.g003){#pgen.1008905.g003}

We next addressed whether a reduction of Pch2 binding to these regions upon transcriptional inhibition could be corroborated through independent, cytological methods. For this, we performed immunofluorescence on spread chromosomes to quantify the chromosomal association of Pch2 during meiotic G2/prophase, and found that a brief inhibition (*i*.*e*. 30 minutes) of active transcription (via Rpo21-FRB nuclear depletion) triggered a significant reduction of Pch2 chromosome-associated foci within synapsed chromosome regions (as identified by staining with the SC component Gmc2 \[[@pgen.1008905.ref046]\]) ([Fig 3H and 3I](#pgen.1008905.g003){ref-type="fig"}). Treatment of cells with Rapamycin for a longer period (*i*.*e*. 90 minutes, [S5A Fig](#pgen.1008905.s006){ref-type="supplementary-material"}) led to similarly reduced chromosomal levels of Pch2 ([S5G Fig](#pgen.1008905.s006){ref-type="supplementary-material"}). The loss of Pch2 from synapsed chromosomes under both these conditions is less penetrant as compared to the loss of Pch2 from chromosomes that is seen in *zip1Δ* cells \[[@pgen.1008905.ref018]\] ([Fig 3I](#pgen.1008905.g003){ref-type="fig"} and [S5H Fig](#pgen.1008905.s006){ref-type="supplementary-material"}). The nucleolar pool of Pch2 (identified by the typical nucleolar morphology and lack of association with SC structures) was not significantly affected by RNAPII inhibition ([S5I Fig](#pgen.1008905.s006){ref-type="supplementary-material"}), suggesting that RNAPII-dependent transcription specifically promotes non-nucleolar recruitment of Pch2. This observation is in agreement with the association of Pch2 with RNAPI-dependent transcriptional activity within the rDNA, as suggested by our ChIP-seq analysis (see above). Together, these data identify active RNAPII-dependent transcription as a factor that positively contributes to the recruitment of Pch2 to euchromatic chromosome regions during meiotic G2/prophase.

We sought to better understand the recruitment of Pch2 to chromosomes, also in light of the connection with transcription. For this, we focused our attention on Orc1, a factor involved in Pch2 recruitment to the nucleolus \[[@pgen.1008905.ref030], [@pgen.1008905.ref039]\]. Orc1 is a component of the Origin Recognition Complex (ORC), a six subunit (Orc1-6) hexameric AAA+ ATPase ([Fig 4A](#pgen.1008905.g004){ref-type="fig"}), and we recently showed, using *in vitro* biochemistry, that Pch2 directly interacts with ORC \[[@pgen.1008905.ref047]\]. The first step in DNA replication occurs when ORC recognizes and directly binds to hundreds of origins of replication (also known as autonomously replicating sequences (ARSs)) across the genome (reviewed in \[[@pgen.1008905.ref031]\]). Given the connection between ORC and Pch2 and the well-established association of ORC with origins, we first queried whether Pch2 was associated with origins. We plotted Pch2 occupancy (log~2~ genome-wide enrichment of Pch2 wild-type and E399Q) around the center of 626 predicted ARSs (from OriDB ([http://cerevisiae.oridb.org](http://cerevisiae.oridb.org/)); this list includes likely and confirmed ARSs). This analysis did not reveal significant enrichment for Pch2 at or around ARSs, and these regions seemed to rather display a local depletion of Pch2 binding ([Fig 4B](#pgen.1008905.g004){ref-type="fig"}). The observation that Pch2 does not significantly associate with origins of replication was confirmed by ChIP-qPCR investigating individual origins ([Fig 4C](#pgen.1008905.g004){ref-type="fig"}). We conclude that Pch2 is not detectably associated with origins of replication during meiotic G2/prophase, hinting that the interaction between Pch2 and Orc1 is established away from origins of replication \[[@pgen.1008905.ref047]\].

![Interplay between Pch2, Orc1 and transcription.\
A. Schematic of Pch2 and ORC, including the domain organization of Orc1. B. 3XFLAG-Pch2 and 3XFLAG-Pch2-E399Q binding (ChIP-seq normalized against the input) plotted relative to the center of ARSs. C. ChIP-qPCR analysis of 3XFLAG-Pch2-E399Q at *PPR1* (primer pair: GV2390/GV2391), *GAP1* (primer pair: GV2597/GV2598), *ARS202* (primer pair: GV2583/GV2584) and *ARS1116* (primer pair: GV2577/GV2578) during meiotic G2/prophase (t = 4 hours). Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. D. ChIP-qPCR analysis of Orc1-TAP and Orc2-TAP at *PPR1* (primer pair: GV2390/GV2391), *GAP1* (primer pair: GV2597/GV2598), *HOP1* (primer pair: GV2605/GV2606), *ARS1116* (primer pair: GV2577/GV2578) during meiotic G2/prophase (t = 4 hours). Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. E. ChIP-qPCR analysis of 3XFLAG-Pch2-E399Q in *ORC1* or *orc1-161* background at *PPR1* (primer pair: GV2390/GV2391) and *GAP1* (primer pair: GV2597/GV2598) during meiotic G2/prophase (t = 4 hours). Experiments were performed at 30°C. Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. F. Representative images of immunofluorescence of meiotic chromosome spreads in 3XHA-Pch2 expressing *ORC1* or *orc1-161* cells collected at 6 hours after induction into the meiotic program. Experiments were performed at 30°C. Chromosome synapsis was assessed by α-Gmc2 staining. Experiments were performed at 30°C. G. Quantification of non-nucleolar Pch2 intensity per spread nucleus for the immunofluorescence analysis shown in F and for immunofluorescence analysis of cells progressing synchronously through meiotic prophase at 4, 5 and hours ([S6A and S6B Fig](#pgen.1008905.s007){ref-type="supplementary-material"}). \*\*\* indicates a significance of p≤ 0.001, Mann-Whitney U test. H. ChIP-qPCR analysis of 3XHA-Pch2-E399Q in *ORC1* or *orc1Δbah* background at *PPR1* (primer pair: GV2390/GV2391), *GAP1* (primer pair: GV2597/GV2598) during meiotic G2/prophase (4 hours). Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate.](pgen.1008905.g004){#pgen.1008905.g004}

Previous studies have described association of components of the replication machinery (including ORC) to actively transcribed, protein coding genes \[[@pgen.1008905.ref048]--[@pgen.1008905.ref050]\], and we thus considered the possibility that ORC exhibited a binding pattern similar to that of Pch2 during meiosis. The binding patterns of Pch2 showed some overlap with the reported association profile of ORC with coding genes in mitosis (*i*.*e*. 60 out of 436 peaks in Pch2 wild type and 4 out of 94 within the additional Pch2 E399Q binding sites) ([S1 Table](#pgen.1008905.s013){ref-type="supplementary-material"}). We analyzed Orc1-TAP binding by ChIP-qPCR: as a positive control, we measured its association to *ARS1116*, and found Orc1 to be highly enriched at this site ([Fig 4D](#pgen.1008905.g004){ref-type="fig"}), indicative of association of Orc1 with chromosomes during meiotic G2/prophase \[[@pgen.1008905.ref039]\]. Strikingly, we also detected substantial binding of Orc1-TAP with *GAP1* and *HOP1*, but not *PPR1*, mirroring Pch2 binding behavior *(*[Fig 4D](#pgen.1008905.g004){ref-type="fig"} and [S6A Fig](#pgen.1008905.s007){ref-type="supplementary-material"}). Similar results were seen for Orc2-TAP ([Fig 4D](#pgen.1008905.g004){ref-type="fig"}). To explore the possibility that Orc1 functions upstream of Pch2 with respect to its localization − as has been suggested within the nucleolus/rDNA \[[@pgen.1008905.ref030], [@pgen.1008905.ref039]\] − we made use of a temperature-sensitive allele of *ORC1*, *orc1-161*. Pre-meiotic DNA replication is delayed for \~1 hour in *orc1-161* cells ([S6B Fig](#pgen.1008905.s007){ref-type="supplementary-material"}), but meiotic progression appears otherwise normal \[[@pgen.1008905.ref030]\]. This mutation severely diminished ORC association with origins of replication (as measured by ORC2-TAP ChIP; [S6C Fig](#pgen.1008905.s007){ref-type="supplementary-material"}) (note that all *ORC1/ORC2* inhibition experiments were performed at 30°C), likely due to a reduction in Orc1 protein levels ([S6D Fig](#pgen.1008905.s007){ref-type="supplementary-material"}) \[[@pgen.1008905.ref051]\]. The levels of Orc2-TAP at *GAP1* were reduced under these conditions ([S6C Fig](#pgen.1008905.s007){ref-type="supplementary-material"}). We next performed Pch2 ChIP-qPCR in yeast strains harboring temperature-sensitive alleles of either *ORC1 (orc1-161)* or *ORC2 (orc2-1)*. As shown in [Fig 4E](#pgen.1008905.g004){ref-type="fig"}, in *orc1-161* cells, Pch2 levels were strongly depleted at *GAP1*, suggesting that Orc1 contributes to the chromosomal association of Pch2, also outside the nucleolus. Pch2 protein levels appeared unaffected under these conditions ([S6E Fig](#pgen.1008905.s007){ref-type="supplementary-material"}), and mRNA levels of selected Pch2-enriched sites (*i*.*e*. *GAP1* and *HOP1*) were not changed in *orc1-161* cells (grown at 30°C) ([S6F Fig](#pgen.1008905.s007){ref-type="supplementary-material"}), arguing against indirect, transcriptional effects of Orc1 on Pch2 recruitment.

We next asked whether other subunits of ORC exhibited a similar connection to Pch2 recruitment. Orc2 was readily detected in *ORC2* cells but barely detected in *orc2-1* cells ([S6G Fig](#pgen.1008905.s007){ref-type="supplementary-material"}). In contrast to the effects seen in *orc1-161*, ChIP-qPCR analysis of 3xHA-Pch2-E399Q revealed no effect of *orc2-1* on recruitment to *GAP1* ([S6H and S6I Fig](#pgen.1008905.s007){ref-type="supplementary-material"}). Thus, although we cannot rule out that incomplete inactivation of Orc2 in *orc2-1* obscures effects on Pch2 recruitment, these data collectively suggest that Orc1 is involved in promoting the chromosomal association of Pch2.

Cytological analysis showed that Pch2 localization to the nucleolus/rDNA is severely impaired in *orc1-161* cells \[[@pgen.1008905.ref030]\]. Our ChIP analysis indicated that Orc1 also contributes to recruitment at non-rDNA loci, and accordingly, using immunofluorescence on spread chromosomes we found that in *orc1-161* cells Pch2 localization was diminished within non-rDNA regions ([Fig 4F and 4G](#pgen.1008905.g004){ref-type="fig"}). Due to the observed delay in premeiotic DNA replication of \~1 hour in *orc1-161* cells (see for example [S6B](#pgen.1008905.s007){ref-type="supplementary-material"} and [S7C](#pgen.1008905.s008){ref-type="supplementary-material"} Figs), a reduction in Pch2 association could be the result of indirect effects of delayed DNA replication on meiotic chromosome metabolism. We thus analyzed Pch2 chromosomal association at different times post induction of meiosis (*i*.*e*. after 4, 5 and 6 hours) and consistently found a significant reduction of Pch2 association with chromosomes in *orc1-161* cells ([Fig 4F and 4G](#pgen.1008905.g004){ref-type="fig"}, and [S7A and S7B Fig](#pgen.1008905.s008){ref-type="supplementary-material"}). Importantly, the significant reduction of Pch2 on meiotic chromosomes in *orc1-161* cells persisted, even when comparing *orc1-161* cells at t = 6 hours with *ORC1* cells at t = 4 hours. For these analyses, we focused on cells that appeared in the same G2/prophase stage, as judged by SC morphology (via Gmc2 staining), again hinting at a direct role for Orc1 in influencing efficient Pch2 chromosomal recruitment.

We cannot fully exclude that subtle defects in DNA replication upon *ORC1* inactivation, indirectly contribute to the observed effects on Pch2. However, together with the observation that Pch2 directly associates with ORC *in vitro* \[[@pgen.1008905.ref047]\], these analyses indicate that ORC (and particularly Orc1) affects the localization of Pch2 at euchromatic chromosomal regions, likely in a direct manner. In addition, we provide evidence below that the ORC/Orc1 effect on Pch2 chromosomal association is correlated with its co-localization within regions of RNAPII-activity.

Orc1 contains a [B]{.ul}romo [A]{.ul}djacent [H]{.ul}omology (BAH) domain, a nucleosome-binding domain \[[@pgen.1008905.ref052]\] that contributes to ORC's ability to bind origins of replication \[[@pgen.1008905.ref053]\] ([Fig 4A](#pgen.1008905.g004){ref-type="fig"}). We and others have revealed a role for the BAH of Orc1 in controlling rDNA-associated functions \[[@pgen.1008905.ref030], [@pgen.1008905.ref054]\], and we interrogated whether occupancy of Pch2 to regions of transcriptional activity was affected in *orc1Δbah* cells. Indeed, deletion of the BAH domain of Orc1 reduced the association of Pch2 to sites of active transcription ([Fig 4H](#pgen.1008905.g004){ref-type="fig"} and [S7D and S7E Fig](#pgen.1008905.s008){ref-type="supplementary-material"}). Collectively, these results suggest that ORC/Orc1 may use its nucleosome-binding capacity (endowed by the BAH domain of Orc1) to bind to and recruit Pch2 to non-canonical (*i*.*e*. non-origin) genomic loci that are defined by transcriptional activity. In light of this, it is interesting to note that Orc1-BAH binding to nucleosomes − in contrast to a related BAH domain in Sir3 \[[@pgen.1008905.ref055]\] − is insensitive to the acetylation state of Histone H4, which could allow effective engagement with (acetylated) nucleosomes within euchromatin \[[@pgen.1008905.ref054]\].

Based on these observations, we explored a potential connection between Pch2 binding patterns and histone modifications. We generated a correlation matrix between Pch2 and published ChIP-seq datasets of a battery of chromatin marks \[[@pgen.1008905.ref056]\]([S8 Fig](#pgen.1008905.s009){ref-type="supplementary-material"}). Since comprehensive meiosis-specific maps of these marks are not available, we performed this analysis with maps generated from vegetatively growing cultures. This analysis revealed the strongest correlations between Pch2 and several modifications that are associated with active transcription \[[@pgen.1008905.ref057]\], such as Histone H3K4-dimethylation and Histone H3S10-phosphorylation. Interestingly, we also detected a correlation with Histone H4K20-monomethylation. Dimethylation of Histone H4K20 is a determining factor in driving ORC association with metazoan origins of replication through the direct recognition of this modification by the BAH domain of metazoan Orc1\[[@pgen.1008905.ref058]\]. Although budding yeast Orc1-BAH does not appear to recognize this modification \[[@pgen.1008905.ref058]\], and Histone H4K20-dimethylation has not been detected in budding yeast, this finding might point to a possible connection between Pch2, Orc1, and Histone H4K20-monomethylation. In addition, Pch2 weakly correlated with Histone H3K79-monomethylation (but to a much lower extent with Histone H3K79-di, and tri-methylation). The Histone H3K79 methyltransferase Dot1 influences Pch2 chromosomal recruitment \[[@pgen.1008905.ref022], [@pgen.1008905.ref023]\], and the affinity of the BAH domain of Orc1 with nucleosomes is likely sensitive to modification of Histone H3K79 \[[@pgen.1008905.ref055]\] \[[@pgen.1008905.ref054]\]. The observed correlation between Pch2 binding and Histone H3K79-monomethylation thus potentially suggests that Dot1 activity influences Pch2 association to sites of active transcription.

In *pch2Δ* cells, abundance of Hop1 on synapsed chromosomes is increased \[[@pgen.1008905.ref015], [@pgen.1008905.ref018], [@pgen.1008905.ref059]\] ([S9A Fig](#pgen.1008905.s010){ref-type="supplementary-material"}). In addition, phosphorylation of Hop1 \[[@pgen.1008905.ref060]\] persists in *pch2Δ* cells \[[@pgen.1008905.ref015]\]([S9B Fig](#pgen.1008905.s010){ref-type="supplementary-material"}). Likewise, conditions that impair Pch2 localization on chromosomes lead to increases in Hop1 chromosomal abundance and phosphorylation status \[[@pgen.1008905.ref015], [@pgen.1008905.ref018], [@pgen.1008905.ref024]\]. We used cytological and ChIP-based approaches to test effects of acute removal of Pch2 from regions of transcriptional activity (via our Rpo21-FRB-based system) on Hop1 chromosomal abundance and function. First, we quantified Hop1 chromosomal association with synapsed chromosomes under conditions where RNAPII-inhibition caused diminished localization of Pch2 (*i*.*e*. 30 minutes long exposures to rapamycin) ([Fig 5A and 5B](#pgen.1008905.g005){ref-type="fig"}, see also [Fig 3H and 3I](#pgen.1008905.g003){ref-type="fig"}). Under these conditions, we did not observe significant changes in Hop1 chromosomal association. We exposed cells to rapamycin for longer periods (*i*.*e*. 90 instead of 30 minutes, see also [S5G Fig](#pgen.1008905.s006){ref-type="supplementary-material"}), and also under these conditions, we did not observe alterations in the abundance of Hop1 on synapsed chromosomes ([S9C Fig](#pgen.1008905.s010){ref-type="supplementary-material"}). These experiments were all performed in early meiotic G2/prophase (*i*.*e*. from 3:30 to 4 or 5 hours into the meiotic program). We also investigated effects later in meiotic G2/prophase (*i*.*e*. after 8 hours in *ndt80Δ* cells, to prevent exit from G2/prophase), when most cells contain fully synapsed SCs, and thus contain significant amounts of Pch2 on chromosomes. Under these conditions, inhibition of RNAPII equally did not lead to significant effects on Hop1 chromosomal recruitment ([Fig 5B](#pgen.1008905.g005){ref-type="fig"} and [S9D Fig](#pgen.1008905.s010){ref-type="supplementary-material"}). We next investigated Hop1 chromosomal levels by ChIP-qPCR, around a known Hop1 binding site in wild type and *pch2Δ* cells \[[@pgen.1008905.ref044]\], but again did not find effects of acute inhibition of RNAPII on Hop1 chromosomal abundance at a selected locus ([S9E and S9F Fig](#pgen.1008905.s010){ref-type="supplementary-material"}). We also probed the accumulation of the phosphorylated version of Hop1 (identified by a slower migrating band on SDS-PAGE gels), which reports on Hop1 'activation' on chromosomes \[[@pgen.1008905.ref044]\]. In accordance with earlier observations, we did not observe differences in the amount of phosphorylated Hop1 under conditions of RNAPII depletion ([Fig 5C and 5D](#pgen.1008905.g005){ref-type="fig"} and [S9B Fig](#pgen.1008905.s010){ref-type="supplementary-material"}). Based on all cumulative experiments, we conclude that impairing the chromosomal association of Pch2 by inhibiting its recruitment to sites of active RNAPII-transcription does not lead to the detectable effects on the chromosomal association and function of Hop1. We also queried whether *ORC1* inactivation (which triggers reduction of Pch2 from chromosomes to a similar level as RNAPII nuclear depletion (Figs [3H](#pgen.1008905.g003){ref-type="fig"}, [3I](#pgen.1008905.g003){ref-type="fig"}, [4F and 4G](#pgen.1008905.g004){ref-type="fig"})), was associated with effects on Hop1 chromosomal accumulation. Similar to what we observed after inhibition of RNAPII, we found that in *orc1-161* cells (queried at t = 4 hours post induction), Hop1 chromosomal levels were not different to those seen in *ORC1* cells ([S9G and S9H Fig](#pgen.1008905.s010){ref-type="supplementary-material"}). Importantly, under these conditions we did detect an increased localization of Hop1 within nucleolar DNA, as expected from the confirmed role of Orc1 in driving Pch2 localization to the nucleolus \[[@pgen.1008905.ref030]\] \[[@pgen.1008905.ref039]\].

![Functional analysis of the transcriptional-associated Pch2 chromosomal population.\
A. Representative images of immunofluorescence of Hop1 on meiotic chromosome spreads in *rpo21-FRB* anchor away cells, treated with DMSO or rapamycin, using the regimen indicated in [Fig 3C](#pgen.1008905.g003){ref-type="fig"}. Chromosome synapsis was assessed by α-Gmc2 staining. B. Quantification of total Hop1 intensity per spread nucleus for the experiment shown in A and [S9D Fig](#pgen.1008905.s010){ref-type="supplementary-material"}. n.s. (non-significant) indicates p\>0.05, Mann-Whitney U test C. Schematic of treatment regimens used for anchor away experiment, as shown in D. D. Western blot analysis of Hop1 and Pch2 (α-HA) in *rpo21-FRB* anchor away *ndt80Δ* cells synchronously progressing through meiotic prophase, treated with DMSO or rapamycin, as indicated above the western blot image. Upon DMSO or rapamycin treatment samples were taken every 30 minutes. Arrow indicates phosphorylated Hop1, \* indicates non-phosphorylated Hop1. See quantification of three independent western blot experiments on [S4 Table](#pgen.1008905.s016){ref-type="supplementary-material"}.](pgen.1008905.g005){#pgen.1008905.g005}

Finally, we aimed to address further requirements for Pch2 association with selected regions of active RNAPII-dependent transcription. Most of the identified binding regions fall within genes that are also transcriptionally active in vegetatively growing cells (with the exception of a subset of meiosis-specific genes). In addition, Orc1/ORC is equally present in vegetatively growing cells. Therefore, we investigated whether ectopic expression of Pch2 − normally only expressed in meiosis − was sufficient to promote association with selected regions of binding, as identified in our ChIP analysis. We generated a galactose-inducible allele of Pch2 (*pGAL10-3HA-pch2-E399Q*) to induce Pch2-E399Q to protein levels comparable to those observed in meiotic G2/prophase ([Fig 6A and 6B](#pgen.1008905.g006){ref-type="fig"}). Of note, in this allele, we removed the intron that is present in the *PCH2* to ensure proper mitotic expression and translation. ChIP-qPCR analysis revealed that, in contrast to the situation in meiotic cells, Pch2-E399Q was unable to associate with *GAP1*, *TDH3* or *DAL4* in mitosis ([Fig 6C](#pgen.1008905.g006){ref-type="fig"} and [S10A Fig](#pgen.1008905.s011){ref-type="supplementary-material"}). We confirmed that *GAP1* was actively transcribed during vegetative growth ([Fig 6D](#pgen.1008905.g006){ref-type="fig"}). These results show that active transcription and presence of Orc1/ORC are not sufficient for the association of Pch2 with selected regions of active transcription, and instead suggest the presence of meiosis-specific factors that 'license' Pch2 binding. In agreement with such a model, we found that during meiosis, Zip1 was required for the recruitment of Pch2 to *GAP1* ([Fig 6E](#pgen.1008905.g006){ref-type="fig"} and [S10C and S10D Fig](#pgen.1008905.s011){ref-type="supplementary-material"}) mirroring the effect seen using cytological approaches \[[@pgen.1008905.ref018]\] ([Fig 3I](#pgen.1008905.g003){ref-type="fig"} and [S5H Fig](#pgen.1008905.s006){ref-type="supplementary-material"}). As such, our results reveal a connection between transcription, ORC/Orc1 function and meiosis-specific chromosome organization that allows the recruitment of a specific chromosomal pool of Pch2 ([Fig 6F](#pgen.1008905.g006){ref-type="fig"}).

![Requirements of Pch2 binding in mitosis and meiosis.\
A. Schematic of allele used for galactose-inducible mitotic expression of 3XHA-Pch2-E399Q. B. Western blot analysis of meiotic (*i*.*e*. endogenous) expression during meiotic G2/prophase at 4 hours after induction into the meiotic program and ectopic expression of *pGAL10-3XHA-pch2-E399Q*. Hours of treatment with galactose are indicated. C. ChIP-qPCR analysis of 3XHA-Pch2-E399Q at *PPR1* (primer pair: GV2390/GV2391), *GAP1* (primer pair: GV2597/GV2598) and *HOP1* (primer pair: GV2605/GV2606) during in meiosis and mitosis. Time (hours) is indicated. Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. D. ChIP-qPCR analysis of active transcription (α−Rpo21-phospho-Ser5) *GAP1* (primer pair: GV2597/GV2598), *HOP1* (primer pair: GV2605/GV2606) in meiosis and mitosis. Hours are indicated. Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. E. ChIP-qPCR analysis of 3XFLAG-Pch2-E399Q at *PPR1* (primer pair: GV2390/GV2391) and *GAP1* (primer pair: GV2597/GV2598) in wild type or *zip1Δ* cells during meiotic G2/prophase (t = 4 hours). Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. F. Model depicting the interplay between Pch2 binding, active transcription, Orc1 and chromosome organization.](pgen.1008905.g006){#pgen.1008905.g006}

Discussion {#sec003}
==========

The AAA+ protein Pch2 controls meiotic DSB formation, influences crossover recombination, mediates a meiotic G2/prophase checkpoint and is involved in chromosome reorganization upon chromosome synapsis (reviewed in \[[@pgen.1008905.ref020]\]). For many functions, the chromosomal association of Pch2 has been postulated to be crucial. During meiotic G2/prophase Pch2 is enriched within the nucleolus/rDNA, and is also detected on synapsed chromosomes \[[@pgen.1008905.ref018]\]. Chromosome synapsis is mediated by the dynamic polymerization of the synaptonemal complex (SC), whose formation is mostly nucleated at sites of crossover recombination \[[@pgen.1008905.ref010]--[@pgen.1008905.ref012]\]. Synapsis-dependent recruitment of Pch2 is abolished in cells that lack Zip1, the central element of the SC \[[@pgen.1008905.ref013], [@pgen.1008905.ref014], [@pgen.1008905.ref018]\]. In addition to Zip1, other factors influence the chromosomal distribution of Pch2: Sir2 and Orc1 promote the nucleolar localization of Pch2 \[[@pgen.1008905.ref022], [@pgen.1008905.ref030]\], whereas Dot1 influences global chromosomal abundance of Pch2 \[[@pgen.1008905.ref022], [@pgen.1008905.ref023]\].

Here, we present a comprehensive analysis of the chromosomal association of Pch2 via genome-wide ChIP-seq. We reveal that Pch2 is associated with a subset of actively transcribed RNAPII-dependent genes. We perform several experiments and analyses to ascertain that these binding patterns are biologically meaningful and not caused by ChIP-associated artefacts \[[@pgen.1008905.ref036]\] (see also Supplementary Data). Recruitment of Pch2 is dependent on active RNAPII-dependent transcription, but transcriptional strength *per se* is likely not the sole determining factor. For example, many actively transcribed genes do not recruit significant amounts of Pch2. If not solely determined by transcriptional strength and specific DNA content, what are additional factors that influence Pch2 association? We found that Orc1, a component of ORC, is required for Pch2 association with actively transcribed genes. Our data further indicate that the requirement of Orc1 to recruit Pch2 to sites of active transcription is likely independent of an effect of Orc1 on the transcriptional activity of these specific genes. In the future, it will be interesting to gain more insight into the interplay and function dependencies between active RNAPII-transcription, Orc1 recruitment, and Pch2 association.

The connection between Pch2 and Orc1 at genomic regions that are distinct from origins of replication further underscores the non-canonical role played by Orc1 during meiotic G2/prophase \[[@pgen.1008905.ref047]\]. In addition, since Orc1 is also involved in nucleolar recruitment of Pch2 \[[@pgen.1008905.ref030], [@pgen.1008905.ref039]\], these findings hint at a common biochemical foundation that underlies recruitment of Pch2 to diverse chromatin environments. A recent study did not detect a role for Orc1 on the chromosomal (non-nucleolar) recruitment of Pch2 \[[@pgen.1008905.ref039]\], and differences in the experimental approaches that were used to interfere with Orc1 function might underlie this discrepancy. Specifically, we used a temperature-sensitive allele of *ORC1* (*orc1-161*) to deplete Orc1, whereas Herruzo *et al*. \[[@pgen.1008905.ref039]\] employed an auxin degron-based method, and conceivably, depletion timing and efficiencies of Orc1 could differ under these conditions. Alternatively, this difference could be explained by the use of distinct strain backgrounds (SK1 versus BR): the chromosomal (*i*.*e*. non-nucleolar) localization of Pch2 in BR strains has been noted to be less pronounced as compared to Pch2 chromosomal localization observed in SK1 strains, used here (for example \[[@pgen.1008905.ref061]\] \[[@pgen.1008905.ref039]\]). In addition, BR and SK1 strains show quantitative differences in Pch2-dependent phenotypes (such as the ability to arrest in response to chromosome synapsis defects observed in *zip1Δ* cells, *e*.*g*. see \[[@pgen.1008905.ref018]\] \[[@pgen.1008905.ref032]\]). We speculate that these observations could reflect strain-specific differential reliance on chromatin recruitment and functionality of Pch2 on certain chromosomal recruitment pathways.

We show here that the Bromo-Adjacent Homology BAH-domain of Orc1, a nucleosome-binding module contributes to targeting of Pch2. BAH domains are readers of chromatin state \[[@pgen.1008905.ref052]\]. A structural characteristic of a related BAH domain (*i*.*e*. that of budding yeast Sir3) is that nucleosome association is sensitive to Dot1-mediated Histone H3 K79 methylation (H3K79me) \[[@pgen.1008905.ref055]\]. Interestingly, Dot1 activity (and H3K79 methylation state) is important for Pch2 localization along chromosomes \[[@pgen.1008905.ref022], [@pgen.1008905.ref023]\]. Dot1 activity is associated with active RNAPII transcriptional activity (reviewed in \[[@pgen.1008905.ref062]\]), and RNAPII transcription-associated Dot1 activity may thus affect binding patterns of Pch2, potentially through Orc1 BAH domain-mediated nucleosome interactions. Of note, by analyzing correlations between our Pch2 data sets with genome-wide maps of several histone modifications \[[@pgen.1008905.ref056]\], we found a relatively higher correlation between genome-wide Pch2 binding and H3K79-monomethylation patterns. We thus speculate that epigenetic status (*i*.*e*. specific chromatin modifications, such as Dot1-dependent H3K79-monomethylation) could contribute to Pch2 recruitment within euchromatin. However, we note that the correlation between Pch2 binding and Dot1-dependent modifications was relatively weak. Dot1 activity limits the general association of Pch2 with chromatin (as judged by cytological assays) \[[@pgen.1008905.ref022], [@pgen.1008905.ref023]\] and it thus remains unclear whether a contribution of Dot1 to transcription-associated Pch2 is a consequence of direct biochemical dependencies. Future biochemical and genome-wide association analysis should be able to provide more insight into the connection between nucleosomes, H3K79-methylation, and Pch2-ORC/Orc1.

Previous work has established that Pch2 localizes to the nucleolus \[[@pgen.1008905.ref022]\], the site of RNAPI-driven rDNA transcription. We note that the nucleolus is a membrane-less, self-organized nuclear compartment that exhibits properties of a liquid-liquid phase separated nuclear condensate (reviewed in \[[@pgen.1008905.ref063]\]). Interestingly, recent work revealed the existence of RNAPII-specific nuclear condensates that influence transcriptional regulation (reviewed in \[[@pgen.1008905.ref037]\]). In the future, it will be interesting to investigate whether the biochemical properties of transcriptional condensates relate to (shared) characteristics for the recruitment and function of Pch2 at RNAPI- and RNAPII-transcriptional hubs.

Meiotic chromosomes are organized into a typical loop-axis structure shaped by active transcription \[[@pgen.1008905.ref003], [@pgen.1008905.ref004], [@pgen.1008905.ref009], [@pgen.1008905.ref064]--[@pgen.1008905.ref069]\]. Our genome-wide mapping revealed that the Pch2 binding patterns are strikingly distinct from the stereotypical binding patterns of meiotic axis factors (*i*.*e*. Hop1, Red1 and Rec8) \[[@pgen.1008905.ref008], [@pgen.1008905.ref009]\]. We suggest that the transcription-associated pool of Pch2 is not directly associated with chromosome axis sites and is instead associated with genes in loop regions. This is somewhat surprising since *i*) the only identified client of Pch2, Hop1 is a component of the axis, and *ii*) assembly of the SC, a structure that is assembled directly on the axis factors, is important to allow Pch2 recruitment to chromosomes. It is conceivable that the interaction between Pch2-associated sites and the chromosome axis is highly dynamic and flexible, and revealing the chromosomal behavior of Pch2 in living cells will be important to understand the organizational principles of Pch2 recruitment onto meiotic chromosomes.

We found clear evidence that both active transcription and Orc1 function promote the recruitment of Pch2 to meiotic chromosomes. Surprisingly, we found that impairing this recruitment pathway was not associated with detectable effects on Hop1 chromosomal association and function. We cannot currently rule out that incomplete inhibition of Pch2 association under the used conditions precludes us from exposing an effect on Hop1 function. Indeed, the effect of RNAPII/Orc1 inactivation on Pch2 recruitment was partial when compared to the (apparently complete) effect seen in *zip1Δ* \[[@pgen.1008905.ref018]\] (see Figs [3I](#pgen.1008905.g003){ref-type="fig"} and [4G](#pgen.1008905.g004){ref-type="fig"}). Nonetheless, our results could indicate that merely disrupting recruitment of Pch2 to meiotic chromosomes is not sufficient to trigger defects in the dynamic association of Hop1 with chromosomes. Recent work, using an Orc1-degradable allele \[[@pgen.1008905.ref039]\], also did not detect an effect of Orc1 inactivation on Hop1 levels and function.

Additional processes, such as chromosome restructuring and/or post-translational modifications of axis factors (*i*.*e*. phosphorylation of *ASY1*, the *Arabidopsis thaliana* homolog of Hop1) \[[@pgen.1008905.ref024], [@pgen.1008905.ref029]\] influence the functional interplay between Pch2 and Hop1 on chromosomes. Under conditions where effects are seen on Hop1 chromosomal association (and Pch2 recruitment) (*i*.*e*. *zip1Δ*, *zip1-4LA*, and *top2-1* \[[@pgen.1008905.ref015], [@pgen.1008905.ref018], [@pgen.1008905.ref021], [@pgen.1008905.ref024]\]*)* such additional requirements would be fulfilled, potentially in contrast to the conditions we describe here.

Alternatively, the pool of Pch2 identified here could play a role that is distinct from the canonical role of Pch2 in the removal of the bulk of Hop1 from meiotic axis sites. Accordingly, interference with recruitment of this Pch2 population (via transcriptional inhibition or Orc1 inactivation) would not be expected to affect the chromosomal association of Hop1. When considering the localization patterns of Pch2 described here, it is thus possible to speculate that more than one chromosomal population of Pch2 exists, of which one is recruited to transcriptionally active regions. In that scenario, a population of Pch2 that is directed to chromosome axis sites (that can possibly not be detected using ChIP-based approaches) might be responsible for the majority of Hop1 removal upon chromosome synapsis. However, under such a scenario, one would expect to be able to detect quantitative effects on Pch2 chromosome foci (as judged by immunofluorescence), where individual foci would be differentially affected by Rpo21/Orc1 inactivation. We, however, did not observe such differential behavior, and instead observed a general decrease in intensities of chromosomal Pch2 foci upon inactivation of Rpo21/Orc1 (for example, see Figs [3H](#pgen.1008905.g003){ref-type="fig"} and [4F](#pgen.1008905.g004){ref-type="fig"}).

We considered a role for Pch2 in transcriptional regulation, and tested this by comparing RNA-seq datasets from *pch2Δ ndt80Δ* and *ndt80Δ* cells. However, we found that these datasets were highly similar, especially when focusing on Pch2-associated genes or meiosis-specific genes ([S11A and S11B Fig](#pgen.1008905.s012){ref-type="supplementary-material"} and [S5 Table](#pgen.1008905.s017){ref-type="supplementary-material"}), suggesting that Pch2 does not affect transcription of genes that are directly associated with. For example, although Pch2 is associated with the *HOP1* gene, we found no significant difference between *HOP1* mRNA levels in *ndt80Δpch2Δ* relative to *ndt80Δ* cells by differential expression analysis (log~2~ fold: 0,190, *p*-value = 0.46, see [S5 Table](#pgen.1008905.s017){ref-type="supplementary-material"}).

What is the role of the transcription-associated pool of Pch2? The connection between Pch2 and synaptonemal complex formation and the contribution of Zip1 to the recruitment of the transcription-associated Pch2 population ([Fig 6](#pgen.1008905.g006){ref-type="fig"}) might provide a clue. SC polymerization along synapsing chromosomes has been proposed to trigger mechanical reorganization \[[@pgen.1008905.ref069]\] \[[@pgen.1008905.ref024]\], which might influence large-scale topological organization of loop-axis structures, and Pch2 localization. Pch2 also influences chromosome organization upon synapsis \[[@pgen.1008905.ref015]\]. Understanding how Pch2 is recruited to transcriptionally active regions, and how this is mechanistically linked to SC function and Orc1 should provide clues to the roles of the chromatin-associated pool of Pch2 we describe here. It will be interesting to understand the link between transcription, chromosome topology, organization and Pch2 recruitment. In addition, Pch2 impacts global DSB activity \[[@pgen.1008905.ref044]\], and the specific recruitment of Pch2 to defined chromosomal regions might conceivably impact local DSB patterning and potentially, genome stability (within actively transcribed regions). Finally, the meiotic functions of Pch2 have been attributed to its biochemical effects on Hop1 (reviewed in \[[@pgen.1008905.ref020]\]), but it is conceivable that the AAA+ ATPase activity of Pch2 acts on additional (potentially HORMA domain-containing) clients whose roles might be related to transcription-associated processes. Clearly, biochemical and genome-wide analysis, coupled to functional investigation will be needed to reveal Pch2 function and regulation during meiotic G2/prophase.

In conclusion, we have used genome-wide methodology to reveal a hitherto unknown relationship between Pch2, active transcription and Orc1, which influences the chromosome synapsis-driven recruitment of Pch2 to euchromatin during meiotic G2/prophase. Future work is needed to understand how the dynamic chromosome recruitment of this important AAA+ ATPase contributes to meiotic DSB formation, recombination and checkpoint signaling.

Materials and methods {#sec004}
=====================

Yeast strains and growth conditions {#sec005}
-----------------------------------

All yeast strains used in this study were of the SK1 strain background, except for the strains harboring the galactose-inducible promoter (*pGAL10*) system, which are of the W303 background. The genotypes of these strains are listed in Supplementary Data. For experiments using mitotically cycling cells (as shown in [Fig 5A--5D](#pgen.1008905.g005){ref-type="fig"}), cells were grown to saturation in YP-D/R medium ((1% (w/v) yeast extract, 2%(w/v) peptone, 0,1%(w/v) dextrose and 2%(w/v) raffinose)) at 30°C. Induction of synchronous meiosis was performed as described in \[[@pgen.1008905.ref030]\]. Cultures were diluted to an optical density at 600nm (OD600) of 0.4, grown for an additional 4 hours after which 2% galactose was added. Unless stated otherwise, samples of cells undergoing synchronous meiosis were collected 4 hours after incubation in sporulation (SPO) medium. Synchronous entry of cultures into the meiotic program was confirmed by flow cytometry-based DNA content analysis (see below). For experiments using temperature-sensitive strains, meiotic induction was performed as described in \[[@pgen.1008905.ref030]\], except that cells were grown for up to 24 hours in pre-sporulation medium (BYTA) at the permissive temperature (23°C). Meiotic cultures were then shifted to 30°C. For the inhibition of global transcription ([S5 Fig](#pgen.1008905.s006){ref-type="supplementary-material"}) 1,10- Phenanthroline (100 μg/mL in 20% ethanol, Sigma-Aldrich) \[[@pgen.1008905.ref041]\] was added to cultures 3 hours after induction into the meiotic program. Cells were subsequently grown for one hour and harvested. For mitotic expression of Pch2-E399Q, the coding sequence of *pch2*-E399Q (lacking its intron) was cloned in a *URA3* integrative plasmid containing *pGAL10-3XHA*. The plasmid was integrated at the *URA3* locus. For expression of 3XFLAG-dCas9 in meiosis, *3XFLAG-dCas9-tCYC1* was cloned in a TRP1 integrative plasmid containing *pHOP1* to create *pHOP1*-*3XFLAG-dCas9-tCYC1*. The plasmid containing *3XFLAG-dCas9/pTEF1p-tCYC1* was a gift from Hodaka Fujii and obtained via [Addgene.org](http://Addgene.org) (Addgene plasmid \#62190) \[[@pgen.1008905.ref071]\].

Nuclear depletion via the anchor-away method {#sec006}
--------------------------------------------

Rpo21 was functionally depleted from the nucleus using the anchor away technique \[[@pgen.1008905.ref042], [@pgen.1008905.ref045]\]. Briefly, Rpo21 was tagged with FKBP12-rapamycin-binding (FRB), and this allele was introduced in strains harboring the anchor away background (*RPL13A-2xFKBP12 fpr1Δ tor1-1)* \[[@pgen.1008905.ref042]\]. Nuclear depletion of Rpo21-FRB was achieved by addition of rapamycin at a concentration of 1 μM. Exact treatment regimens are indicated per experiment (see figure legends). For viability assays, serial dilutions of mitotically growing yeast cells were spotted on solid YPD containing 1 μM rapamycin for 2 days.

Co-immunoprecipitation and western blots {#sec007}
----------------------------------------

100mL of SPO cultures (OD600 1.9), were harvested at 3000 rpm for 3 min at 4°C and washed once with ice-cold Tris-buffered saline (TBS) buffer (25 mM Tris--HCl, pH 7.4, 137 mM NaCl, 2.7 mM KCl). Cells were snap-frozen in liquid nitrogen and stored at -80°C until further use. Cells were resuspended in lysis buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 1% Triton X-100, and 1mM EDTA) containing protease inhibitors and broken with glass beads using bead beater (FastPrep-24, MP Biomedicals; 2 X 60 seconds at speed 6.0, incubated on ice in between for 5 min). Chromatin was sheared by sonication using a Bioruptor (Diagenode), 25 cycles of 30 seconds on/off, high power at 4°C. Lysates were clarified by centrifugation for 15 min at 16,000 x g at 4°C. Lysates were then immunoprecipitated with α-TAP antibodies using magnetic beads (Invitrogen), washed 4 times with buffer containing detergent and another time with the same buffer without detergent. Beads were eluted in 1X loading buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 12.5 mM EDTA, 0.02% bromophenol blue) and the supernatant resolved by SDS-PAGE followed by Western blotting. Protein extracts were prepared by using trichloroacetic acid (TCA) extraction protocol as previously described \[[@pgen.1008905.ref030]\]. Samples were resolved by SDS-PAGE, transferred to nitrocellulose membranes and probed with the following primary antibodies diluted in 5% (w/v) nonfat-milk in TBS buffer + 0.1% Tween 20: α-Flag (Sigma-Aldrich, F3165, 1:1000), α-ORC2 (Abcam, 31930, 1:500), α-HA (BioLegend, 901502, 1:1000), α-TAP (Thermo Scientific, CAB1001, 1:2000), α-Pgk1 (Invitrogen, 459250, 1:5000), α-Rpo21 (BioLegend, 664906, 1:500), α-phosphoserine 5 Rpo21 (Thermo Scientific, MA518089, 1:1000), α-Histone-H3 (Abcam, AB1791, 1:1000), α-FRB (Enzo, ALX215-065-1, 1:500), α-Zip1 (Santa Cruz Biotechnology, YC-19, 1:1000), α-Hop1 (kind gift of Nancy Hollingsworth, Stony Brook University, Stony Brook, USA, 1:5000), α-β-Actin (Abcam, AB170325, 1:5000), α-Histone H2A (Active Motif, AB2687477, 1:1000) or α-ORC (kind gift of Stephen Bell, MIT, Cambridge, USA, 1:2000). Membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG, anti-mouse IgG and donkey anti-goat IgG (Santa Cruz Biotechnology). Proteins were detected with ECL (GE Healthcare) using a digital imaging system Image-Lab (Bio-Rad).

Chromatin Immunoprecipitation (ChIP) {#sec008}
------------------------------------

For ChIP experiments, 100 mL SPO-cultures (OD600 1.9) were harvested 4 hours after entering meiosis, unless stated otherwise. Meiotic cultures or exponentially growing mitotic cultures were crosslinked with 1% methanol-free formaldehyde for 15 minutes at room temperature and the reaction quenched with 125 mM Glycine. Cells were washed with ice-cold TBS, snap-frozen and stored at --80°C. Cells were resuspended and broken with glass beads using a bead beater, as described above. Chromatin was sheared using either a Branson Sonifier 450 (microtip, power setting 2, 100% duty cycle, 3X for 15sec, 2 min on ice in between) or using a Diagenode Bioruptor UCD 200 (25 cycles of 30 seconds on/off, high power at 4°C). Cells were centrifuged at 13000 rpm for 10 min at 4°C. 10% of sample was removed for input. 550 μl of cell lysates were pre-incubated with the following antibodies for 3 hours at 4°C prior to overnight incubation under rotation with magnetic Dynabeads-protein-G (Invitrogen): for ORC ChIP, 1 μl of α-ORC and 1 μl of isotype control antibody (α-rabbit IgG (Bethyl, P120-101)). For TAP ChIP, 1 μl of α-TAP, and for HA ChIP, 1 μl of anti-HA. For RNA Pol-II ChIP, 1 μl of α-Rp021 or α-phosphoserine 5 Rpo21. Immunoprecipitates were incubated and washed as described above. For FLAG ChIP cells lysates were incubated with 30μl of 50% α-Flag-M2 affinity gel (Sigma-Aldrich, A2220) for 3 hours. Bound proteins were eluted using a 3XFLAG peptide (Sigma-Aldrich, F4799) as described in \[[@pgen.1008905.ref072]\]. For Hop1 ChIP, 50mL SPO-cultures (OD600 1.9) were processed as above and cells were resuspended in 400μl FA-lysis buffer (50 mM HEPES-KOH, pH 7.5; 140 mM NaCl, 1mM EDTA, 10% Glycerol, 1% Triton X-100, 0.1% sodium deoxycholate, + protease and phosphatase inhibitors). Cell breakage and chromatin shearing were performed as above. Dynabeads-Protein-G (Invitrogen) were previously blocked overnight with a solution containing 1μg/μL BSA (Sigma) and 1μg/μL Yeast tRNA (Invitrogen) in TBS. Chromatin was incubated with 1 μl of α-Hop1 or 1 μl of the isotype control (rabbit IgG) for 3 h at 4°C prior to overnight incubation under rotation with blocked magnetic beads. Beads were washed as above with ice-col FA-lysis buffer. Subsequent steps (*i*.*e*. reversal of crosslinking, Proteinase-K and RNase-A treatments and final purifications and elutions) were performed as previously described in \[[@pgen.1008905.ref073]\].

ChIP-Seq library preparation {#sec009}
----------------------------

Preparation of paired-end sequencing libraries was performed using the Illumina TruSeq ChIP library preparation kit--Set-A (15034288), according to the manufacturer's guidelines. Ligation products were size-selected (250--300 bp) and purified from a 2% low-melting agarose gel using the MinElute Gel Extraction Kit (Qiagen). Ampure XP beads (Agilent) were used for cleanup steps and size selection. The final purified product was quantitated using Picogreen in a QuantiFluor dsDNA System (Promega). Paired-end sequencing (2 X 150bp) was performed on the Illumina HiSeq 3000 platform at the Max Planck Genome Centre (Cologne, Germany). The ChIP-seq raw data employed in this study are deposited at the NCBI Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>), under accession no. GSE138429.

Processing of ChIP seq data {#sec010}
---------------------------

Preliminary quality control of raw reads was performed with FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Illumina raw reads were filtered for removal of low quality and duplicated reads, adapters and low-quality bases using the SAM tools (version 1.2). Paired-sequencing reads from three biological independent replicas (ChIPed DNA and their respective inputs from 3XFLAG-Pch2 and 3XFLAG-tagged-Pch2-E399Q expressing cells) were mapped to the yeast genome S288C (SacCer3) using *Bowtie2* (version 2.3.4.3) with default parameters. Non-unique reads were removed using SAMtools (Version 1.2). The dataset was pooled and the Model-based Alignment of ChIP-Seq (MACS2) program was used to call peaks of Pch2 occupancy using the input as a control (*P*-value = e10^-15^). The data visualized on IGV \[[@pgen.1008905.ref074]\] were normalized to the number of Reads per Kilobase per Million (RPKM) of total mapped reads. Bin size was set to 25. For analysis shown in [S3A Fig](#pgen.1008905.s004){ref-type="supplementary-material"}, peak calling was performed as above for NLS-GFP ChIP-seq data (SRR2029413) \[[@pgen.1008905.ref036]\]. For ChIP-seq analyses shown in [Fig 2A and 2B](#pgen.1008905.g002){ref-type="fig"}, and [S4A and S4B Fig](#pgen.1008905.s005){ref-type="supplementary-material"}, processed ChIP-seq data were retrieved from the Gene Expression Omnibus (GEO), access number: GSE69232 (Hop1: GSM1695721; Red1: GSM1695718; and Rec8: GSM1695724) \[[@pgen.1008905.ref009]\]. For [S8E Fig](#pgen.1008905.s009){ref-type="supplementary-material"}, processed ChIP-seq data were obtained from \[[@pgen.1008905.ref044]\], GEO, access number: 105111, (wild type; GSM2818425 and, *pch2Δ*; GSM2818432). Peaks were visualized on IGV \[[@pgen.1008905.ref074]\]. For analysis shown in [S2A Fig](#pgen.1008905.s003){ref-type="supplementary-material"}, datasets were from \[[@pgen.1008905.ref036]\], retrieved from the National Center for Biotechnology Information (NCBI) Short Read Archive under accession number SRP030670. GFP_NLS ChIP-seq and inputs \[[@pgen.1008905.ref036]\].

RNA-Seq {#sec011}
-------

10 mL of yeast undergoing meiosis at 4h (OD600 1.9) was harvested at 1000g for 5 min at 4°C. Cells were washed with ice-cold TE buffer and mechanically lysed with glass beads. Samples were centrifuged for 2 min at full speed and transferred to a new microcentrifuge tube. 1 mL of 70% ethanol was added to the homogenized lysate. Total RNA was then extracted and purified using the RNeasy RNA isolation kit (Qiagen), including treatment with DNase. RNA integrity was assessed by urea RNA-PAGE and quantitated with Quantifluor (Promega). Enrichment of mRNA, library preparation and sequencing was performed by the Max Planck-Genome Centre (Cologne, Germany). Briefly, rRNA was depleted using the Ribo-zero rRNA removal kit (Epicentre). mRNA was enriched using oligo-dT beads (New England Biolabs) and the cDNA library was prepared using the TrueSeq RNA sample preparation kit (Illumina) according to the manufacturer's instructions. Samples were then sequenced on an Illumina HiSeq-3000 instrument. The RNA-seq raw data employed in this study are deposited at the NCBI Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>), under accession no. under accession no. GSE144835.

RNA-Seq data analysis {#sec012}
---------------------

Raw reads were firstly examined and quality trimmed using the FastQC package (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). Reads were filtered and mapped to the S288c genome assembly R64 (sacCer3) using Hisat2 (Version 2.1.0), with default parameter settings. Analyses and quantification of transcripts were performed using the HTSeq (Version 0.9.1) and DESeq2 (2.11.40.6), respectively. The number of mapped reads and comparison of transcripts expression level were estimated using TPM (Transcripts Per Million fragments) values. The log~2~ fold changes of transcripts (TPM) was used to estimate differential expression levels. Transcripts with--log~10~ of P-value \> 2 and log~2~ fold changes ≥ or ≤ 2.0 were considered as significantly differentially expressed. In [S1E Fig](#pgen.1008905.s002){ref-type="supplementary-material"}, expression levels of *ndt80Δ* strains (normalized RNA-seq count data expressed as Transcription per Million---TPM) were stratified as low (0.5--10), medium (\>10--1000) and high (\>1000). For [S11 Fig](#pgen.1008905.s012){ref-type="supplementary-material"}, transcripts presenting baseline expression below 5 (log2 = 2,32) were considered as non-expressed as defined by analyses of basal transcription levels of RNA-seq experiments performed in cells undergoing meiosis. For [S2F Fig](#pgen.1008905.s003){ref-type="supplementary-material"}, the Pearson correlation was calculated with normalized read counts scores (Log~10~) for each Pch2-wild-type binding gene. Expression values for each gene (TPM, Log~10~) were obtained from the RNA-seq data (*ndt80Δ*), processed data available at GEO: GSE144835. For [S11B Fig](#pgen.1008905.s012){ref-type="supplementary-material"}, the list of genes known to be involved in the budding yeast meiosis was retrieved from the KEGG pathway <https://www.genome.jp/kegg/pathway.html> \[[@pgen.1008905.ref075]\].

Computational analyses {#sec013}
----------------------

To plot the enrichment within specific regions, annotation tracks, including the tracks from ChIP-seq data were converted into BED files using The UCSC Genome Table Browser (<https://genome.ucsc.edu/cgi-bin/hgTables>). Yeast tRNAs coordinates were obtained from SGD ([http://www.yeastgenome.org](http://www.yeastgenome.org/)). Autonomously Replicating Sequences (ARSs) (coordinates and sequences for the 626 (dubious ARSs were excluded from the analysis) origins were downloaded from the OriDB (version 2012 ([http://www.oridb.org](http://www.oridb.org/))). Distance map plots analyses were performed with the bamCompare tool (Version 2.5.0) \[[@pgen.1008905.ref076]\] with the following parameters: bin size 50, pseudo count 1.0, limiting the operation to specific regions (Pch2 binding sites, ARSs, tRNAs). The Pch2-ChIP-seq data and the inputs were normalized and compared to compute the log~2~ ratio of the normalized number of reads. The enrichment was calculated as log~2~ ratio of the normalized number of reads: All analyses were carried within the Galaxy platform \[[@pgen.1008905.ref076]\]. Pairwise correlation (Spearman) among Pch2-ChIP seq and Input replicas was estimated using multiBamsummary tool (version 2.5.0). The bin size was set to 200bp and regions with very large counts (which artificially increases correlation) were removed. To compute the correlation between different ChIP-seq datasets, mapped and filtered reads (ChIP-seq data mapped reads normalized against their respective inputs), were computed using the parameters described above. Correlation matrices were created for Pch2-ChIP-seq and Hop1, Red1, Rec8 (GSE69232) \[[@pgen.1008905.ref009]\], and for a different set of histone modifications obtained from \[[@pgen.1008905.ref056]\] (from vegetatively growing yeast strains; GEO61888 and SRA accession numbers within for both ChIP and input data): H4K20me, H3K4me, H3S10phospho, H4K16, H36Kme2, H3K26me2, H2ak5ac, H4k5ac, H4K8ac, Htz1, H3K79me, H3K18ac, H3K4me3, H3K4me3, H3K27ac, H3K4me2, H3K56ac, H3K23ac, H3K14ac, H3K4ac, H2As129phospho, H4R3me2 H3K79me3, H3K79me2. The Spearman correlation matrix was generated with the plot correlation tool (version 3.3.0) \[[@pgen.1008905.ref076]\]. Venn diagrams were generated using the web-based Venn diagram generator from [http://jura.wi.mit.edu/bioc/tools/venn.php](http://jura.wi.mit.edu/bioc/tools/venn.php.%C2%A0To). To determine whether the Pch2 binding genes were enriched in certain functional categories, gene ontology analysis was conducted using the SGD GO term finder (molecular function) (<https://www.yeastgenome.org/goTermFinder>) at a p-value cut-off of 0.01.

ChIP-qPCR {#sec014}
---------

ChIP and Input samples were quantified by qPCR on a 7500 FAST Real-Time PCR machine (Applied Biosystems). The percentage of ChIP relative to input was calculated for the target loci as well as for the negative controls. Enrichment \[relative to time untagged control or IgG (control)\] was calculated using the ΔCt method as follows: 1/(2\^\[Ct−Ctcontrol\]). Primer sequences (including primer efficiency) covering the various loci are listed in the Supplementary Data.

RNA extraction and RT-qPCR {#sec015}
--------------------------

For RNA extraction, 15 mL meiotic cultures were harvested and total RNA was extracted using the hot-acidic phenol method \[[@pgen.1008905.ref077]\], with some minor modifications. Cells were resuspended in 600 μl of freshly prepared TES buffer (10 mM Tris-Cl, pH 7.5 10 mM EDTA 0.5% SDS). 600 μl of acidic-phenol (Ambion) was added and the solution was immediately vortexed vigorously for 30 seconds. Samples were incubated at 65°C for 90 min under rotation at 300 rpm. The solution was kept on ice for 10 minutes and spun down at 14000 rpm for 10 minutes at 4°C. The aqueous top layer was transferred to a new tube and 600 μl of chloroform was added and immediately vortexed. Cells were centrifuged as above after which the aqueous layer was transferred to a new pre-chilled eppendorf tube. RNA was precipitated overnight at -20°C with 2.5 volumes of 100% ethanol and 10% (v/v) sodium acetate, pH 5.4 and washed with 75% ethanol. After drying on ice, RNA was eluted with RNase free water and stored at -80°C. cDNA was generated using the superscript-III reverse transcriptase (Invitrogen) according to the manufacturer's protocol. Briefly, 1--2 μg of total RNA was used in a 20 μl reaction mixture using random primer mix or oligodT-20 (Invitrogen). Relative amounts of cDNAs of various genes were measured by real-time quantitative PCR (RT-qPCR) on a 7500 FAST Real Time PCR machine (Applied Biosystems). The experiment depicted on [S6F Fig](#pgen.1008905.s007){ref-type="supplementary-material"} was performed using the CFX-Connect Real Time PCR detection system (Bio-Rad). Expression of every gene was normalized to the expression of *18S* (RNA Pol I transcript) or β-Actin (*ACT1*) using the 2\^-ΔΔCt method. Oligo sequences and their respective amplification efficiencies are available in Supplementary Data.

Chromosome spreads and immunofluorescence {#sec016}
-----------------------------------------

Chromosome spreading was performed as described in \[[@pgen.1008905.ref015]\]. For immune staining, the following antibodies were used: α-HA (Roche, 11867423001, 1:200), α-Zip1 (Santa Cruz Biotechnology, YN-16, 1:500), α-Gmc2 (a kind gift of Amy MacQueen, Wesleyan University, Middletown, CT, USA, 1:200), α-Rp021 (BioLegend, 664906, 1:200) and α-Hop1 (homemade, 1:2000). α-Hop1 was raised against full-length 6-His-tagged Hop1 expressed in bacteria. Hop1 was purified via affinity purification followed by ion-exchange chromatography, and used for immunization. Antibody production was performed at the antibody facility of the Max Planck Institute of Molecular Cell Biology and Genetics (Dresden, Germany). DNA was stained with 4\',6-Diamidine-2\'-phenylindole dihydrochloride (DAPI). Images were obtained using a DeltaVision imaging system (GE Healthcare) using a sCMOS camera (PCO Edge 5.5) and 100x 1.42NA Plan Apo N UIS2 objective (Olympus). Deconvolved images (SoftWoRx software 6.1.l and/or z-projected) using the SoftWoRx software 6.1.l). were quantitated using Imaris Software (version 9.3.0) (Oxford Instruments). To estimate the intensity of Pch2 signal, we first created a surface by selecting the green channel (Gmc2) and excluded the foci (red channel-- 3XHA-Pch2) located outside of the selected surface. We then estimated the intensity solely covering the green surface. Estimation of intensity of the nucleolar Pch2 pool was performed by creating a region of interest surrounding the nucleolus and measuring the Pch2 signal not covering the Gmc2 surface. Hop1 intensity was carried out in a similar fashion with the quantification of Hop1 signal within the Gmc2 surface. All values were normalized against the background. Scatterplots were created using the Graphpad program (Prism) and statistical significance was assessed using a Mann-Whitney test.

Supporting information {#sec017}
======================

###### Supplementary Data.

(DOCX)

###### 

Click here for additional data file.

###### 

A. Co-immunoprecipation experiment showing an interaction between 3XFLAG-Pch2 and Orc1-TAP. Pgk1 was used as a control. B. Spore viability analysis of the indicated strains. Cells were sporulated for 24 hours in liquid media. The total analyzed tetrads/strain are indicated. C. Representation of meiotic G2/prophase progression in used strain. SC appearance was detected using Gcm2. For each time point 125 cells were counted. D. Genome browser view representative images (RPKM; see also [Material and Methods](#sec004){ref-type="sec"}) of ChIP and input signals for 3XFLAG-Pch2 and 3XFLAG-Pch2-E399Q. Shown is a region of Chromosome *XII* (chromosomal coordinates (kb) are indicated) identical to ChIP-seq binding patterns as shown in [Fig 1C](#pgen.1008905.g001){ref-type="fig"}. E. High resolution Genome browser view representative images (RPKM; see also [Material and Methods](#sec004){ref-type="sec"}) of 3XFLAG-Pch2 and Hop1 binding patterns (from \[[@pgen.1008905.ref044]\]) across two selected chromosomal regions (chromosomes *XI* and *IX*), identical to ChIP-seq binding patterns as shown in [Fig 1D](#pgen.1008905.g001){ref-type="fig"}. Chromosomal coordinates and gene organization are indicated.

(TIFF)

###### 

Click here for additional data file.

###### 

A and B. Heatmap matrices depicting correlation analysis for Pch2 ChIP-seq and Input replicates as measured by the Spearman correlation coefficient (R-values within the squares). C. Scatter plot correlation analysis of Pch2-ChIP-seq (Wild-type versus E399Q) normalized read counts (Log10---RPKM) measured by the Pearson correlation coefficient R-values (upper right corner). D. Normalized read counts (ChIP/input) for 3XFLAG-Pch2 and 3XFLAG-Pch2-E399Q during meiotic G2/prophase, as determined by ChIP-seq. E. Comparison between expression strength of Pch2-associated genes and the transcribed genes from our mRNA dataset (*ndt80Δ* cells) binned into high, medium and low expression strength (following previously established procedures \[[@pgen.1008905.ref035]\]). F. Correlation between normalized reads (log~10~) of 3XFLAG-Pch2 individual binding sites and mRNA expression values (Transcription Per Million). G. ChIP-qPCR analysis of 3XFLAG-Pch2-E399Q at *PPR1* (primer pair: GV2390/GV2391) and *GAP1* (primer pair: GV2597/GV2598) during meiotic G2/prophase (4 hours). H. ChIP-qPCR analysis of active transcription (α-phosphoserine 5 Rpo21) at *PPR1* (primer pair: GV2390/GV2391) and *GAP1* (primer pair: GV2597/GV2598) during meiotic G2/prophase (t = 4 hours). I. Western blot analysis of expression of 3XFLAG-Pch2, 3XFLAG-Pch2-E399Q and 3XFLAG-*Δ*NTD-Pch2 during meiotic G2/prophase (t = 4 hours). J. ChIP-qPCR analysis of 3XFLAG-Pch2, 3XFLAG-Pch2-E399Q and 3XFLAG-*Δ*NTD-Pch2 at *PPR1* (primer pair: GV2390/GV2391), *GAP1* (primer pair: GV2597/GV2598), *HOP1* (primer pair: GV2607/GV2608), *TDH3* (primer pair: GV2591/GV2592), and *SSA1* (primer pair: GV2587/GV2588) during meiotic G2/prophase (t = 4 hours). Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate.
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Click here for additional data file.

###### 

A. Venn diagram comparing 3XFLAG-Pch2 binding peaks and HyperChIPpable regions as described by \[[@pgen.1008905.ref001]\]. B. 3XFLAG-Pch2 and 3XFLAG-Pch2-E399Q ChIP-seq normalized read counts enrichment normalized to inputs (log~2~). Datasets were aligned relative to centre of tRNAs. C. ChIP-qPCR analysis of 3XFLAG-Pch2 and 3XFLAG-dCas9 at *PPR1* (primer pair: GV2390/GV2391) and *GAP1* (primer pair: GV2597/GV2598) during meiotic G2/prophase (4 hours). Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. D. Western blot analysis of 3XFLAG-Pch2 and 3XFLAG-dCas9 as used in C.
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###### 

A and B. Representative images of ChIP-seq binding patterns for 3XFLAG-Pch2, Hop1, Red1 and Rec8. Data for Hop1, Red1 and Rec8 are from \[[@pgen.1008905.ref009]\]. Shown is the entire chromosome *I* (A) and a region of chromosome *III (B)* (chromosomal coordinates (kb) are indicated).
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###### 

A. Schematic of 1,10- Phenanthroline treatment regimen as used for C-D B. mRNA quantification of *GAP1* (primer pair: GV2597/GV2598)*/18S (*primer pair: GV2717/ GV2718) in cells (wild type or 3XFLAG-Pch2-E399Q) treated with mock (20% EtOH) or 1,10- Phenanthroline (final concentration is 2% EtOH and 100 μg/ml 1,10- Phenanthroline). C. Western blot analysis of 3XFLAG-Pch2 in cells (wild type or 3XFLAG-Pch2-E399Q) treated with mock or 1,10- Phenanthroline. D. ChIP-qPCR analysis of 3XFLAG-Pch2-E399Q at *PPR1* (primer pair: GV2390/yGV2391), *GAP1* (primer pair: GV2597/GV2598) in cells (wild type or 3XFLAG-Pch2-E399Q) treated with mock or 1,10- Phenanthroline. Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. E. Western blot analysis of Rpo21 (α-FRB or α-Rpo21) in wild type and *rpo21-FRB* anchor away strains, upon treatment with DMSO or rapamycin, treated as described in [Fig 3C](#pgen.1008905.g003){ref-type="fig"}. F. Representative image of immunofluorescence of Hop1 and Rpo21 on meiotic chromosome spreads. G. Quantification of non-nucleolar Pch2 intensity per spread nucleus in cells treated with DMSO or rapamycin for 90 minutes, according to the scheme indicated in [Fig 3C](#pgen.1008905.g003){ref-type="fig"}. H. Representative image of immunofluorescence of Pch2 on meiotic chromosome spreads in *ndt80Δ* and *ndt80Δzip1Δ* cells, as quantified in 3H. I. Quantification of nucleolar Pch2 intensity per spread nucleus in cells treated with DMSO or rapamycin. n.s. (non-significant) indicates p\>0.05, Mann-Whitney U test.
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###### 

A. ChIP-qPCR analysis of ORC (α-ORC) along the *GAP1* locus during meiotic G2/prophase (4 hours). Primers pair 1: GV2595/GV2596, 2: GV2597/GV2598, 3: GV2599/GV2600. Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. B. Flow cytometric analysis of *ORC1* and *orc1-161* cells (wild type, or expressing or 3XHA-Pch2-E399Q). Time (hours) after induction into the meiotic program is indicated. Experiment was performed at 30°C. C. ChIP-qPCR analysis of Orc2-TAP at *PPR1* (primer pair: GV2390/GV2391), *GAP1* (primer pair: GV2597/GV2598) and *ARS1116* (primer pair: GV2577/GV2578) in *ORC1* and *orc1-161* cells. Experiment was performed at 30°C. Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. D. Western blot analysis of Orc1 and Orc2 (α-ORC) in *ORC1* and *orc1-161* cells. Experiment was performed at 30°C. E. Western blot analysis of 3XHA-Pch2 (α-HA) in *ORC1* and *orc1-161* cells. Hours after induction into the meiotic program indicated. Experiment was performed at 30°C. F. Gene expression of ORFs *PPR1* (primer pair GV2390/GV2391), *GAP1* (GV2597/GV2598), and *HOP1* (primer pair GV2605/GV2606) relative to β-Actin (*ACT1*; primer pair GV2717/GV2718) in *orc1-161* and *ORC1* cells grown at 30°C. Relative gene expression of the reference strain (*ORC1*) was set to 1. G. Western blot analysis of Orc1 and Orc2 (α-ORC) in *ORC2* and *orc2-1* cells. Experiment was performed at 30°C. H. Flow cytometric analysis of *ORC2* and *orc2-1* cells (wild type, or expressing or 3XHA-Pch2-E399Q). Hours after induction into the meiotic program indicated. Experiment is performed at 30°C. I. ChIP-qPCR analysis of 3XHA-Pch2-E399Q at *PPR1* (primer pair: GV2390/GV2391) and *GAP1* (primer pair: GV2597/GV2598) in *ORC2* and *orc2-1* cells. Experiment was performed at 30°C. Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate.
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###### 

A and B. Representative images of immunofluorescence of meiotic chromosome spreads in 3XHA-Pch2 expressing *ORC1* or *orc1-161* cells collect at 4 hours (A) or 5 hours (B) after induction into the meiotic program. Experiments were performed at 30°C. For quantification see [Fig 4G](#pgen.1008905.g004){ref-type="fig"}. C. Flow cytometric analysis of *ORC1* and *orc1-161* cells of cells that were analyzed in [Fig 3F and 3G](#pgen.1008905.g003){ref-type="fig"}, and S7A and S7B Fig. Time (hours) after induction into the meiotic program is indicated. Experiment was performed at 30°C. D. Western blot analysis of 3XHA-Pch2 and Orc1 (α-HA and α-ORC) in *ORC1* and *orc1Δbah* cells. Hours after induction into the meiotic program indicated. E. Flow cytometric analysis of *ORC1* and *orc1Δbah* cells (wild type, or expressing 3XHA-Pch2-E399Q). Hours after induction into the meiotic program indicated.
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###### 

Hierarchically clustered heatmap based on correlation coefficients using from 3XFLAG-Pch2-wild type ChIP-seq datasets as inputs. Data for histone modifications are from \[[@pgen.1008905.ref056]\]. Spearman correlation values are indicated.
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###### 

A. Representative image of immunofluorescence of Hop1 and Gmc2 on meiotic chromosome spreads in *pch2Δndt80Δ* and *ndt80Δ* cells. B. Western blot analysis of Hop1 and Pch2 (α-HA) in *rpo21-FRB* anchor away *ndt80Δ* and *pch2Δndt80Δ* cells progressing synchronously through meiotic prophase, treated with DMSO or rapamycin, as indicated above the western blot image. Arrow indicates phosphorylated Hop1, \* indicates non-phosphorylated Hop1. C. Quantification of total Hop1 intensity per spread nucleus after treatment as indicated. n.s. (non-significant) indicates p\>0.05, Mann-Whitney U test. D. Schematic of treatment regimen used for anchor away experiment for which quantification is shown in [Fig 5B](#pgen.1008905.g005){ref-type="fig"}. Representative immunofluorescence of meiotic chromosome spreads in the 3XHA-Pch2 expressing *rpo21-FRB* anchor away cells, treated with DMSO or rapamycin as indicated. Chromosome synapsis was assessed by α-Gmc2 staining. E. Representative images of Hop1 ChIP-seq binding patterns in wild type and pch2*Δ* from \[[@pgen.1008905.ref044]\]. Chromosome coordinates and primer pairs are indicated. F. ChIP-qPCR analysis of Hop1 in *rpo21-FRB* anchor away strains, upon treatment with DMSO or rapamycin, treated as described in [Fig 2C](#pgen.1008905.g002){ref-type="fig"}. Primers are described in \[[@pgen.1008905.ref044]\]. Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. G. Representative images of immunofluorescence of Hop1 on meiotic chromosome spreads in *ORC1* or *orc1-161* cells collect at 4 hours after induction into the meiotic program. Experiments were performed at 30°C. Chromosome synapsis was assessed by α-Gmc2 staining. \*Indicates nucleolar region. H. Quantification of total Hop1 intensity per spread nucleus (as shown in [S4G Fig](#pgen.1008905.s005){ref-type="supplementary-material"}) after treatment as indicated. n.s. (non-significant) indicates p\>0.05, Mann-Whitney U test.
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###### 

A. ChIP-qPCR analysis of 3XHA-Pch2-E399Q at *PPR1* (primer pair: GV2390/GV2391), *GAP1* (primer pair: GV2597/GV2598) during meiosis, and of *PPR1* (primer pair: GV2390/GV2391), *GAP1* (primer pair: GV2597/GV2598) and *TDH3* (primer pair: GV2591/GV2592) and *DAL4* primer pair: GV2601/GV2602) during mitosis. Time (hours) is indicated. Error bars represent standard error of the mean of at least three biologically independent experiments performed in triplicate. B. Western blot analysis of 3XFLAG-Pch2 and Zip1 (α-FLAG and α-Zip1) in wild type and *zip1Δ* cells. Time (hours) after induction into the meiotic program is indicated. C. Flow cytometric analysis of wild type and *zip1Δ* cells (wild type, or expressing 3XFLAG-Pch2-E399Q). Time (hours) after induction into the meiotic program is indicated. D. mRNA quantification of *GAP1*(primer pair: GV2597/GV2598) *(*primer pair: GV2717/GV2718) or *PPR1* (primer pair: GV2390/GV2391)*/*β-Actin (*ACT1;* primer pair: GV2747/GV2748) in wild type or *zip1Δ* cells during meiotic G2/prophase (4 hours).

(TIFF)

###### 

Click here for additional data file.

###### 

A. Pearson's correlation analysis between expression levels (log~2~ TPM) of *ndt80Δ* and *pch2Δndt80Δ*. B. RNA seq-differential expression values from *pch2Δndt80Δ* relative to *ndt80Δ*, for all genes, wild type Pch2-binding and KEGG pathway (meiosis) genes. C. Histogram depicting the Log~2~ normal distribution of averaged TPM values from ndt80 strains RNA-seq. The defined expression cut-off (red line, see [methods](#sec004){ref-type="sec"}) and the range of TPM of 3X-FLAG-Pch2-wild type binding genes (green line) are indicated.
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###### List of Pch2 binding CDS sites.
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###### Gene Ontology (GO) terms of Pch2 binding ORFs.
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Click here for additional data file.

###### Underlying numerical data of main results.
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Click here for additional data file.

###### Western blot quantification of selected blots presented in the manuscript.

(XLSX)
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Click here for additional data file.

###### Differential expression analysis (log2 fold) of *ndt80Δpch2Δ* relative to *ndt80Δ* cells.

(XLSX)
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Click here for additional data file.
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13 Nov 2019

Dear Gerben,

Thank you very much for submitting your Research Article entitled \'Active transcription and Orc1 drive chromatin association of the AAA+ ATPase Pch2 during meiotic G2/prophase\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised substantial concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review a much-revised version. We cannot, of course, promise publication at that time.

Reviews are given at the bottom of this letter; however, I (ML) would like to emphasize two points in particular:

1\. A major concern that I (ML) had, and that reviewers expressed, involves the use of \"peak shape score\" as a proxy for occupancy in the analysis of ChIP-seq data. As far as I can tell (and the reference describing this metric is pretty opaque on the issue), this is a metric that can be independent of actual occupancy levels\--for example, a sharp peak in a region of low background occupancy could have a higher score than a broad peak of higher occupancy levels in a region of high background occupancy. My suspicion is that differences in actual occupancy profiles in the ChIP-seq experiments (i.e. ChIP/input) are much smaller, and it is of course this value, not one reflecting peakiness, that is of actual biological relevance. Given this concern, I think that it is important to provide corresponding ChIP-seq profiles that report ChIP/input ratios for the regions examined (e.g. Figure 1C, D, Fig 4A, Fig S5, Fig S6F) and to provide ChIP-qPCR values for primer pairs at peak loci (i.e. GAP1, HOP1, etc) not only within the \"peak\" area but also outside them. I think that it is likely that the reduction in Pch2 occupancy seen under conditions of Pol2 inhibition/depletion and of ORC mutants are going to turn out to be regional rather than gene body-specific, but of course that remains to be seen. I believe that this concern is also what underlies reviewers\' requests for additional ChIP-seq data. It must be emphasized that this is a [critical]{.ul} concern; until true occupancy data are in hand, it will not be possible to evaluate the biological significance of the experiments. 

2\. A second concern involves the experiments with *orc* mutants. In general, the defect in Pch2 occupancy seems to parallel defects in replication; *orc1-161* and *orc1-∆BAH* show delayed replication, while *orc2-1* does not. It seems quite possible that, at the 4h time point when ChIP is done, some aspect of meiotic chromosome structure is incompletely established in mutants where replication is compromised, and this, rather than a direct Orc1 interaction, is responsible for the observed effects. Unless the Pch2-Orc1 interaction can be disrupted without affecting replication dynamics, this will remain an open question, and the conclusions regarding the contribution of Orc to Pch2 recruitment will need to be substantially revised.

Further editorial comments are given below immediately before the reviewers\' comments. 

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer and the editor. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. I apologize for the absence of numbers in comments from reviewers 1 and 3\--please fell free to insert numbers as you see fit if it will help in crafting your response. 

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <plosgenetics@plos.org>. 

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Michael Lichten, Ph.D.

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

AE\'s additional comments:

3\. (comments 1 and 2 are in letter body, above). PLOS has a very strict data availability policy (please see letter body, above and journals.[plos.org/plosgenetics/s/data-availability](http://plos.org/plosgenetics/s/data-availability)). In particular, the term \"data not shown\" is verboten; either show data or revise the text so that the statement is not necessary.

a\. Relevant lines in the manuscript are 157, 160-4, 252, 254, 329 and 392; for line 153, I suggest that you simply say that the current paper describes Pch2 occupancy patterns in non-rDNA sequence, and that binding patterns in rDNA will be described elsewhere.

b\. The ChIP-seq data need to be made available to reviewers, so please give the password in manuscript on line 521\--reviewers do not have access to the cover letter. 

c. For all figure panels with graphs, please provide the data underlying each graph. This can most easily be by including an Excel workbook with a separate worksheet for each panel. For example, for Figure 1F, please include all values for each primer pair in both tagged and untagged strains. (This need not be done with very data-dense panels such as 1C, D or E).

4. Figure legends\--I assume that by "standard error" you mean standard error of the mean; please clarify, and also please clarify what "at least three independent experiments performed in triplicate" means---and how SEM was calculated. Were there three sets of three values, or just three values?

5. Fig S1C---correlation seems to be driven entirely by genes with no expression. Once these are eliminated, the is probably not correlation at all.

6\. line 67: Red1 shares no homology to SYCP2/3; better to make clear that the proteins are functional analogs but do not share significant homology.

7\. line 137: Capitalize Materials and Methods; please use 10(superscript)-15 rather than 1e-15

8\. Figure 1F---given the apparent absence of Pch2 from sequences up- and down-stream of GAP1, it would seem a good idea to include qPCR primers for these regions, as well; this would be a good control for the Pol2 ChIP as well (see AE comment 2, above).

9\. Figure 1G---please quantify FLAG/Pgk1 ratios; it appears that Pch2 243-564 is present at substantially lower levels. Is Pch2 243-564 localized to the nucleus?

10\. Other western blots---please quantify and present ratios for the following; Figure 1B, 2G, 4F (including upshifted Hop1), 5B, S4B, S4E, S4F, S4I. For Figure S7C, it will be important to have the Zip1 and zip1∆ samples on the same blot, to determine whether or not Pch2-E399Q levels are similar in both strains. Ratios can be reported under each lane, or, if it makes figures too crowded, in a supplementary table.

11\. Figure S1B---why is RNA-seq under High, Medium and Low, while mRNA levels is under all 4?

12\. Figure S3A---was the phenanthroline treatment here as shown in panel B?

13. Figure S4F---at what time in meiosis were these protein samples taken?

14\. Figure S6F---please provide Y axis labels and values. I could find no such images in Subramanian et al, and am assuming that you re-analyzed their data. Please provide full information for this analysis, including the datasets analyzed, method used, etc. 

15\. Please proofread references and correct title capitalization, italicization of genes and species, journal abbreviations, etc. 

16\. Please carefully read the instructions to authors (<https://journals.plos.org/plosgenetics/s/submission-guidelines>) and follow formatting instructions (helpful examples can be downloaded) in crafting the revision. 

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: Notes on Pch2 PLoS Genetics Manuscript

In this manuscript, Cardoso da Silva et al. examine the meiotic chromosome localization of Pch2, a highly conserved and important regulator of meiotic recombination. The key experiment here - Pch2 ChIP-Seq - is of high interest to the field and one that is potentially very informative about Pch2\'s regulation and functions. It has the potential to help us understand Pch2\'s seemingly diverse roles: in controlling the localization of the recombination regulator Hop1 on chromosomes, in suppressing recombination in the repetitive rDNA, and in its mysterious checkpoint-like function in mutants with compromised inter-homolog synapsis.

While the topic is of high relevance and the data interesting, I can\'t recommend publication without significant revisions to address a number of major and minor questions/concerns, which are listed in detail below. In summary, while the authors have identified a set of Pch2-localizing sites on chromosomes in meiotic prophase, they do not adequately explain how Pch2 gets to these sites (yes, it\'s transcription and Orc1-dependent, but why?), nor do they reveal any biological role for these localization sites. That is, the sites identified do not seem relevant to Pch2\'s most well-recognized function, in Hop1 remodeling/removal; this may be a consequence of the depletions etc. being done too late in meiotic prophase to see a difference. The authors also inexplicably fail to present some seemingly very relevant data and analyses, noting them as \"unpublished observations\": this includes data on Pch2\'s localization to rDNA, which would arguably be one of the most interesting features of their ChIP-Seq dataset, and an analysis of Pch2 ChIP-Seq compared to various histone modifications. I am also somewhat concerned about the peak-calling algorithm, and features of some figures that suggest that the observed Pch2 localization is very weak.

Finally, I hate to suggest excessive extra work in a review, preferring instead to review the material as presented. Nonetheless I can\'t help but note that the manuscript would be much stronger if ChIP-Seq had been performed instead of ChIP-qPCR for many comparisons. This would allow genome-wide correlations of, e.g., Pch2 and Orc1 localization in meiotic prophase, Pch2 localization in mitotic cells, etc. etc. On a similar note, because meiotic prophase stage is so very important in understanding Pch2 function, a time-course for Pch2 localization (at selected sites by ChIP-qPCR or better, by ChIP-Seq) would be extremely informative.

Major comments/concerns:

Page 6 - The authors do most of their assays four hours after induction of meiosis. What stage of meiotic prophase are these cells in? I can imagine that catching Pch2 in its (presumably) most physiologically-relevant state - during synapsis, when it is localizing to chromosomes and remodeling/removing Hop1 from the axis - might be difficult to accomplish. If the cells are pre-zygotene or already in pachytene by this analysis, what is the relevance of the localization the authors are mapping?

Page 6 - Please describe \"peak shape score\" in more detail. From my quick literature search, this seems to be a score generated by a robust \"learning\" peak-calling method, but it bears some explanation in the text. For example, what is a \"good\" peak shape score?

Page 6 - The authors note (several times) the fact that they observed Pch2 localization to the rDNA by ChIP, yet choose not to describe it in this manuscript. I can\'t see why it\'s excluded; it seems very relevant to our understanding of how Pch2 works.

Figure 1E does not make sense to me. If the authors are averaging the ChIP-Seq signal over \~500 peaks, why is the shape of this graph so jagged, instead of smooth? Also, why is the signal seemingly so low? It seems from the graph that the baseline level is 0.8 ChIP-Seq/Input (log2 ratio), while the peaks are only 0.92? Can this be right? The peaks are only 1.9-fold enriched over background binding, and the background is somehow 1.75-fold enriched over background? What\'s going on here? If these are the real ratios, is the peak-calling algorithm just enhancing noise? Figure 3B is also much more jagged than expected from an average of many peaks.

Figure 2I, 3G, and (maybe) 4D) - It seems that counting the number of foci of Pch2 (Hop1 in Figure 4D) is not really the right way to quantify the data. There is obviously a dramatic reduction in overall intensity of chromosome-associated Pch2 in Rapamycin treatment and orc1-161 cells (assuming the panels are intensity-matched), but the number of foci changes much less than the overall intensity. Is there are way to quantify overall Pch2 intensity per nucleus, rather than number of foci?

Is ORC localized to origins of replication in meiotic prophase? If not, Pch2 localization there would not be expected.

The authors cite a work by Shor et al. (ref. \#45) that identified a large number of ORC-binding sites in highly-transcribed genes close to replication origins. Have the authors compared this set of genes to their own identified sites? TDH3, UTH1, and SSA1 are on the list of previously-identified \"ORF-ORC sites\" (not GAP1, however). The meiotic genes would not have been identified in that prior analysis, but it still may be a worthwhile comparison.

On the subject of the above comment, it seems that Shor et al. showed that the \"ORF-ORC\" sites are all pretty close to origins. Have the authors looked at the proximity of their identified Pch2 peaks to origins, comparing that proximity to that of the typical gene to an origin?

One more comment on the above, given the authors\' experiments with Pch2 expression in mitosis seems to have shown no localization with GAP1, what about analyzing other sites? It seems that the authors should at minimum examine several other loci, or ideally perform ChIP-Seq again on these cells to compare all sites. It could be that GAP1 is atypical of sites (and HOP1 is not transcribed in mitosis - this is a fine negative control, but doesn\'t invalidate this point).

Regarding the authors\' result that deletion of the Orc1 BAH domain compromises Pch2 localization to gene bodies: Orc1\'s BAH domain is known to localize to H3K20 methyl marks, at least in other species. Can the authors comment on the possibility that the peaks they identify might be enriched in this mark, perhaps specifically in meiosis, for some reason?

Figure 4 - The experiment measuring Hop1 localization to chromosomes when disrupting Pch2 localization to gene bodies needs to be explained better. The interpretation of this data depends very strongly on what stage the cells are in during these measurements: If they are in leptotene/zygoetene, the authors can reasonably argue that the Hop1 they are measuring is the population of Hop1 that is promoting DSBs and COs prior to synapsis. If the cells are in pachytene during this analysis, then the authors are only looking at the \"residual\" Hop1 that remains on synapsed chromosomes, and is presumably not (or only weakly) promoting DSBs/COs. In the same vein, also matters a lot how long Pch2 localization has been compromised (i.e. if the Rapamycin was added after synapsis and the completion of Pch2\'s Hop1-removal task, then its depletion from chromosomes would not be expected to affect Hop1 levels.

Related to the above point: Lines 333 and 334, the authors state that PNAPII depletion did not cause differences in the amount of phosphorlyated Hop1 (Figure 4E-F). But again this experiment was done entirely in pachytene, after the bulk of phosphorylated Hop1 had been removed/degraded/dephosphorylated. Depleting RNAPII during the meiotic prophase stage when Pch2 activity is most relevant for Hop1 (zygotene) would seem to be more informative.

Discussion - the authors note that the Orc1 BAH domain may in fact associate with Dot1-mediated H3K79 methylated nucleosomes, and state that they detected a correlation between Pch2 ChIP-Seq and H3K79 methylation; but do not show this data. Why not? I think an important supplemental figure would be to show a correlation analysis of Pch2 ChIP-Seq peaks with every histone modification for which a dataset is available. Are any such datasets available from meiotic cells?

When discussing the loop-axis structure of meiotic chromosomes, the authors should cite two recent Hi-C papers by Muller\...Koszul (Mol Syst Biol 14(7):e8293) and Schalbetter\...Neale (Nature Communications 10(1):4795, October 2019) describing the yeast loop-axis structure in detail, and perhaps also the mammalian-cell Hi-C papers by Alavattam et al (NSMB 2019), Wang et al. (Mol Cell 2019), Patel et al. (NSMB 2019), and Covadonga Vara et al. (Cell Reports 2019)

Minor points:

Figure 1F - this would be much more useful if the authors added one or a couple probes outside the ChIP-Seq peak for GAP1.

Line 148: Reference Supplementary Fig. 1A.

Line 185-188: Please double check with the figure reference.

Line 234 - \"PolI\" should be \"PolII\"

Reviewer \#2: This work by Cardoso da Silva et al. reports the association of Pch2 with a subset of chromosomal regions containing genes that are actively transcribed by RNA polymerase II during meiosis. In fact, active transcription is required for Pch2 recruitment to those sites. Paralleling the previously known role of Orc1 (a subunit of ORC) in Pch2 localization to the rDNA, this study shows that Orc1, but not Orc2, is also required for Pch2 binding to selected gene bodies in euchromatin. However, unlike ORC, Pch2 is not detected at replication origins. In addition, Zip1 is also needed for Pch2 association to transcribed regions. However, impairment of Pch2 chromatin recruitment by depletion of the Rpo21 component of RNAPII does not result in any effect in Hop1 chromosomal distribution and abundance, suggesting that the chromosomal population of Pch2 described in this work is not involved in regulating Hop1 function.

Given the importance of Pch2 in the control of various aspects of meiotic chromosome metabolism, the findings reported in this manuscript are interesting in the meiosis field. The experiments performed in this work are very well executed, the results are clear and, for the most part, support the conclusions presented. The main weakness of this paper is that it does not provide any insight into the possible biological relevance for meiosis of the transcription-associated population of Pch2 reported here.

Major comments/concerns

1\) Immunolocalization of Rpo21-FRB on chromosome spreads in the absence of rapamycin (+DMSO) shows a rather exclusive pattern with that of Zip1 in the single nucleus presented in Figure 2D. Curiously, this pattern is reminiscent of Hop1 localization, also displaying an alternative distribution with Zip1 on wild-type prophase I chromosomes (San-Segundo and Roeder, Cell 1999; Joshi et al., PLoS Genetics 2009). The authors could test whether Rpo21 foci, representing transcription sites, and Hop1 colocalize.

2\) Figures 2H, 2I (as well as Figures S6B, S6C) conclude that depletion of Rpo21 leads to fewer Pch2 chromosomal foci without affecting nucleolar Pch2. From the representative nuclei shown, it appears that, upon Rpo21 depletion, Pch2 foci are not only fewer, but also weaker. This raises the question of whether the remaining foci represent the same population of Pch2 that depends on transcription with lower amount of Pch2 loaded or, alternatively, that those Pch2 remaining foci correspond to an Rpo21-independent population and, therefore, may be involved in Hop1 chromosome exclusion. In other words, since by ChIP-seq only one chromosomal fraction of Pch2 is detected, which is transcription-dependent and not involved in Hop1 distribution, do the cytological assays detect only this same population? First, quantification of the Pch2 nucleolar signal relative to chromosomal Pch2 must be performed to definitely state that the nucleolar pool is unaffected. Second, colocalization between Hop1 and Pch2 before and after Rpo21 depletion must be assessed and quantified to determine if the population of Pch2 that remains after transcription inhibition shows a different chromosomal distribution relative to Hop1 or there is some degree of overlap. Also colocalization between Gmc2 and Pch2 (-/+ Rapamycin) should be quantified.

3\) This same issue applies to Figures 3F, 3G, where Pch2 localization is analyzed in the orc1-161 mutant. How is Hop1 distribution/abundance in the orc1-161 mutant? Is Orc1 only required for recruitment of the transcription-associated chromosomal Pch2 pool not involved in Hop1 removal from the SC axes, or it also affects the other proposed population of Pch2 presumably acting on Hop1?

4\) The authors view as "striking" the observation that Pch2 ChIP-seq peaks do not coincide with Hop1-enriched (axis) sites. Given the assumption that Pch2 removes Hop1 from chromosomes, I would consider that result as "expected". Another question is the finding that the ATP-hydrolysis defective Pch2-E399Q version neither shows overlap with Hop1 regions; this is more surprising. As the authors explain in the manuscript, Pch2-E399Q is expected to remain locked to its client(s)/substrate(s)/adaptor(s). Indeed, according to this notion, cytological assays have shown that, in contrast to wild-type Pch2, Pch2-E399Q extensively colocalizes with Hop1 both at the rDNA and chromosomes (Herruzo et al., NAR 2016). Consistent with the prediction for a more stable interaction with the substrates, Pch2-E399Q displays stronger chromatin binding compared to Pch2 as shown in Figure S1A. The authors speculate that there are two chromosomal populations of Pch2, one associated to certain transcribed regions and another one, undetectable by ChIP, responsible for Hop1 removal. Why this second pool cannot be detected, at least in the case of Pch2-E399Q, if it remains locked to Hop1, and Hop1 is detectable? What is the direct evidence that this second population of chromosomal Pch2 does exist? Do the cytologically detectable Pch2 foci represent both populations? (Please, see points 2 and 3).

5\) The authors speculate that chromatin modifications may influence Pch2 binding to certain transcribed genes. Since Sir2 and Dot1 are the usual suspects in this context, it would be interesting to determine whether these chromatin modifiers are required for Pch2 recruitment to gene bodies.

6\) The finding that Pch2 binds to a subset of transcribed genes during meiosis, raises the possibility of a possible role for Pch2 in regulating transcription that is not addressed in the manuscript. It is curious that one of the genes bound by Pch2 is HOP1. It has been shown that global levels of the Hop1 protein are increased in the pch2 mutant (Ho and Burgess, PLoS Genetics 2011), although the underlying molecular mechanism is currently unknown. Figure 4F shows that Hop1 protein levels and Hop1 phosphorylation do not appear to be significantly affected upon Rpo21-FRB depletion, a condition that prevents Pch2 binding to transcribed genes. However, quantification and repeats of this WB analysis, including pch2 deletion as control for comparison, should be provided. Also, since some low amount of Pch2 bound to genes may remain in the Rpo1-FRB depletion assay, to definitely rule out a role for Pch2 in HOP1 transcription, HOP1 mRNA levels in the pch2 deletion mutant should be analyzed.

Minor points:

1\) Figures 1G and 1H show that elimination of the NTD of Pch2 impairs Pch2 binding to selected target genes. Thus, the authors conclude that the NTD is required for Pch2 recruitment to transcribed gene bodies. Although, the conclusion is formally correct, it is possible that the NTD is not directly involved in recruitment, but in the formation or stability of the Pch2 hexameric complex.

2\) What do the asterisks indicate in Figures 2H and S6B? The rDNA? Please, explain in the legends

3\) Evidence for functionality of the 3xFLAG tagged version of Pch2 must be provided

4\) In the WB of Figure 1B the Pch2 protein is detected at t=0 using anti-FLAG antibodies, but not in Sup Fig S4E using anti-HA antibodies? Is that an antibody issue?

5\) Line 148: Supplementary Figure 1B should be 1A

6\) Line 168: Supplementary Figure 1C should be 1B

7\) Line 171: Supplementary Figure 1D should be 1C

8\) Line 185: Supplementary Figure 1E should be 1D

9\) Line 188: Supplementary Figure 1F should be 1E

10\) In page 1 of Supplementary data, Supplementary Figure 1D should be 1C

11\) In page 2 of Supplementary data, Supplementary Figure 1B should be 1A

Reviewer \#3: Overview.

Here the authors have used whole-genome analysis and genetics to investigate the role of the the AAA+ ATPase Pch2 during meiosis in S. cerevisiae, a widely employed model system for studying the mechanisms of recombination and chromosome segregation. The authors identify regions of enriched binding along chromosomes and draw connections to the locations of genes, which is a very different pattern of enrichment to that observed for axis-associated proteins like Rec8 and Hop1. Connections with active transcription are not convincing, and it is not clear that the point the authors are trying to make is well supported. Initial data use whole-genome maps, but most of the data is targeted Q-PCR at a small number of loci. Given the differences across loci that the NGS ChIP-seq data reveals, it is not clear how representative the Q-PCR loci are. ChIP-seq in other mutants (rather than just Q-PCR) would certainly strengthen the validity of the conclusions. From a technical standpoint, I am not convinced by the use of \"Peak shape score\" to plot (and analyse?) raw ChIP-seq data. Is this a quantitative measure of enrichment? Or just a measure of how \"good\" a peak there is in the data? I offer below a number of comments that I think will help to strengthen and improve the clarity of the presented research.

General comment.

The text would benefit greatly from inserting more paragraph breaks and, ideally, section headings so that the logical flow from one idea/figure to the next is clear to the reader. The current text is presented, largely, as one continuous body of text that is hard to traverse.

Specific comments.

Line 131-132. Where are the individual datasets presented? Where is the demonstration that they are highly correlated? I suggest the authors include a correlation between each of the binned datasets. Plotting, as overlays, the individual datasets along part of a chromoosme may also help them make this point.

Line 135. The rationale for the manner in which data are processed and peaks are called is not well described nor justified. This leads to a number of questions that require clarification:

What does \"Peak shape score\", the Y-axis of plots in Fig 1C, 1D (and elsewhere) mean?

Is it actually a quantitative measure of binding, or just a measure of how well (confident?) the algorithm identified a peak?

What if most of the signal is dispersed, and the real signal doesn\'t inherently have peaks?

Do peaks represent the majority, or the minority, of the signal reported?

the use of a very stringent threshold for peak-calling raises alarm bells to this reviewer\...how biased is the subset that are being analysed to only those regions with a particular \"shape\" and or \"strength\"?

What do the data look like if plotted as a more traditional signal/input?

Line 138. The fact that the peaks arise in only a subset of RNAP PolII genes is hardly surprising, when the thresholding used means that there are only a (relative) handful of peaks being analysed\...is this a fair description of the data?

Line 140\...The statement that 3% of peaks arose elsewhere is somewhat misleading. The question in this reviewer\'s mind is: How much of the enriched signal was present within the called peaks?

Fig 1C. Plotting the locations of ORFs would be helpful to see a wider trend of correspondence.

Fig 1D. Equally, plotting a wider area than displayed in Fig 1D would aid the comparison. More importantly form this plot it is not clear what the message is. Are all these genes enriched ? (They seem to be.) Clarifying the description of these data would greatly help the reader.

Line 143 and Fig 1E. The analysis of correspondence with gene structure (and absenece in promoters) would be strengthened by a figure similar to 1E, but where the analysis/pileup point is the gene promoter (and/or terminator). The two plots together would help to demonstrate the enrichment within ORFS and (stated, but not demonstrated) exclusion from promoters.

Labelling for Sup Fig 1 seems to have got mixed up. I think all the panels are one letter out.

Figure referencing used below is based on the submitted figure labelling, not the text.

Fig S1A. How many peaks were present in both samples? A correlation of the shared set of peaks would be informative to determine if, on average, the same peaks are stronger in the mutant (or variable?), or whether the global increase reported is because they represent different peaks detected in the mutant.

Line 163. Where is the data shown to support this statement that all genes occupied by Pch2 are transcribed during meiosis? What (arbitrary) cut-off was used to determine which genes are meiotically transcribed? Is it to do with induction? Or absolute level? These data and conclusions are not currently convincing.

Indeed, Fig S1B, C seems to directly indicate that Pch2-bound genes span the entire spectrum of gene expression levels.

Moreover, Line 169, requires revision: Fig 1C is about as close to no correlation (r\^2=0.0026) as one can get\... Why, then does the text state that a weak correlation was detected? The authors may wish to compute the correlation they (may) observe between the same number of random values for comparison\...

Separately, is it known whether \"Peak shape score\" is a quantitative measure? Perhaps there is a correlation between fold enrichment and expression, but not one between \"Peak shape score\" and expression, for example.

Line 173-179. The experiments performed by the authors to try to rule out ChIP artefacts are good, but certainly require a more thorough summary in the main text. The authors point out where artefacts may arise, so quite simply they then need to succinctly state (in the main text) how they are able to rule them out systematically. This will strengthen, not weaken, the main text.

Fig S3A. Minor. Is 20% EtOH, the final concentration? What concentration is the drug?

Fig S3B. Minor. I suggest placing this schematic before Fig S3A.

Line 231. It would strengthen the conclusion if the published zip1D experiments (reported to show complete loss of Pch2) were repeated alongside the new experiments reported here for RNA Pol inhibition or depletion. i.e. Is it possible that this is a lab/reagent/analysis difference rather than a real difference? If this cannot be done, a qualification can be included to this effect.

Line 232. It is perplexing why the authors hypothesise the effect may indicate incomplete inhibition when the data presented directly demonstrate this to be the case (Fig. 2E).

Line 250-252. Please clarify this point. In the previous sentence the fold enrichment of Pch2 is assayed around 798 annotated ARSs (nothing to do with Pch2 peaks). Why then would adjusting the p-value threshold for Pch2 peaks make any difference? Are the authors themselves clear about what analyses they have performed?

Lines 303-310 and Fig 4A. Without further description and validation, I remain sceptical about plotting data Y-axis as \"Peak shape score\". Is this a known quantitative value that measure enrichment of these factors? Can these data be plotted as more simple fold enrichment instead? Also, an X-Y plot of binned Pch2 enriched signal vs the other factors would help to understand if this is a global quantitative positive, negative, or wholly absent relationship.

Line 328. Under ndt80D conditions, isn\'t most Hop1 already lost on chromosomes? Is there dynamic range to observe an effect?

Would performing anchor-away Pch2 be helpful here (positive control) perhaps?

Lines 329-330. This part of the sentence is confusing. Perhaps clarify that loci used for analysis of Hop1 were identified based on prior datasets.

Lines 331-332. Please clarify what the hypothesis is here with respect to investigating Hop1 phosphorylation state.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: No: ChIP-Seq data should eventually be deposited somewhere

Reviewer \#2: Yes

Reviewer \#3: No: The Pch2 dataset is not currently available publicly: <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138429>

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

10.1371/journal.pgen.1008905.r002
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\* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. \*

Dear Gerben,

Thank you very much for submitting your Research Article entitled \'Active transcription and Orc1 drive chromatin association of the AAA+ ATPase Pch2 during meiotic G2/prophase\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some aspects of the manuscript that should be improved.

Below, some commentary on the reviewers' comments:

Reviewer 1: these should be easily addressed

Reviewer 2: This reviewer had three major concerns.

Biological significance. I think that this is a concern that should be addressed in the discussion. For the difference between your conclusions and those in reference 39, I think that a bit more explicit discussion of what the differences in experimental approaches were, and why they might produce a difference in results, would be warranted. A quick read of that paper indicates that, as you say, there was very little non-nucleolar Pch2 detected (I think that this might be due to how images were thresholded, but I leave it to you to decided); also, ref 39 used a functional readout for Pch2 activity (checkpoint activation in zip1∆) that might actually be the difference between SK1 and BR, since BR zip1∆ mutants arrest and SK1 only delays. Again, I think that a more explicit discussion of this and other issues is warranted.With regards to the main concern, that of biological relevance, both your data and the data in reference 39 indicate that loss of Orc1 function does not have the same phenotype as a pch2 mutant, both with regards to Hop1 distributions and checkpoint function. The question remains then as to what the biological function is of Orc1-dependent Pch2 recruitment to transcriptionally active regions, and it would be useful to include at least some thoughts as to what function that recruitment might serve.  This concern involved the relationship between transcription and Orc1 and Pch2 recruitment. I agree with the reviewer that a trivial explanation would be that Orc1 is necessary for transcription of genes to which Pch2 is recruited. This should be relatively easy to address, either by looking at a couple of Pch2-marked genes, or by seeing if any data exists in the literature regarding the effect of orc1 mutants on gene expression. The question of whether or not transcription is required for Orc1 binding to these genes could, to my mind, be addressed by discussing the issue in an even-handed manner. The reviewer had concerns about the apparent contradiction between the correlation between Pch2 and H3K79me1, on one hand, and biological evidence that Dot1 limits Pch2 localization to euchromatin. Given the rather weak nature of the Pch2-H3K70me correlation, I think that it remains to be shown if this correlation reflects a direct or indirect effect, and I think that it would be wise to somewhat moderate the conclusions in this section. 

Reviewer 3: [All]{.ul} the concerns of this reviewer need to be addressed, but it appears to me that most can readily be addressed by providing additional information in the text or in supplement without additional experimentation. However, I do wish to amplify the reviewer's point regarding Supplementary Figure 1F, where it is abundantly clear that the regression line is being driven almost entirely by the points with expression values of \~0.8, and that removal of this subset would result in no correlation at all. In light of this, I would suggest that the conclusions be altered to say that transcriptional strength is [not]{.ul} a factor that determines Pch2 binding.

Finally, this reviewer suggested (in their first point \#1)(!) dividing the text further into paragraphs. I agree that this will increase readability and suggest the following lines as dividing points, to be divided after the full stop unless otherwise indicated. It would help if paragraphs were indented throughout the manuscript.

Line 134, at start

Line 154, at start

Line 170

Line 237

Line 257

Line 315

Also, please consider the following:

Line 331, suggest "we provide evidence below"

Line 395, suggest "also transcriptionally active"

Line 529-30, redundant with Lines 525-6

Throughout Materials and Methods, please provide antibody dilutions used.

References---improved, but journal abbreviations are still inconsistent.

Figures---for ChIP-seq graphs, please indicate bin sizes and provide units for "normalized reads" (i.e. such as reads per million per 10kb) in either the figure itself or the legend. 

We ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition we ask that you:

1\) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2\) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our [archive](http://www.plosgenetics.org/article/browse/volume). If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Michael Lichten, Ph.D.

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors have done a good job addressing the most pressing and substantive questions and concerns brought up by all the reviewers. While it\'s still a mystery why Pch2 localizes to a subset of transcribed genes in meiosis, I am convinced that it does indeed do so. I just have a couple of minor points for the authors to address before acceptance:

Phenanthroline is mis-spelled twice, I believe.

Figure 2B - labels along the top are in the opposite order from what they should be.

Figure 6E - it's a little confusing to have "zip1d" on a different line than "3XFLAG-Pch2-E399Q" - can the authors move it to the same line?

Reviewer \#2: In this revised version of the manuscript by Cardoso de Silva et al. the authors have performed additional work and they have satisfactorily addressed and/or responded to most of the concerns raised to the previous version. However, there are still some issues that, in my opinion, remain to be solved.

1\. Although the discussion regarding the possible existence of different populations of Pch2 with different functions (one presumably undetectable by ChIP-seq affecting Hop1 and another one detectable by ChIP-seq with no effect on Hop1, but both of them cytologically detectable) has been softened and additional possibilities are now mentioned, my main concern with this article still is the lack of some biological relevance for the transcription-dependent binding of Pch2 to chromosomes.

2\. The authors now succinctly present some ChIP-seq data on the binding of Pch2 to the rDNA region describing that it binds to the RNAPI-transcribed 25S region. Since Orc1 is also required for Pch2 nucleolar targeting there could be also a connection between Orc1 and transcription by RNAPI in the rDNA. I agree that the detailed characterization of the Pch2 rDNA targeting is beyond the scope of this paper, but the possible connection between Orc1 and transcription on the "euchromatin" could be further explored. This paper describes that Pch2 recruitment to chromosomes requires Orc1 and requires RNAPII transcription, but the dependence/relationship between Orc1 and transcription is not analyzed. In other words, is Orc1 required for transcription at the ORFs bound by Pch2? Is transcription required for Orc1 binding to those ORFs? I don't really like bringing up new issues during revision, but the results presented in the revised version lead to these questions that should be addressed or, at least, further discussed.

3\. The authors now present a correlation analysis between genomic distribution of Pch2 and a panel of histone modifications obtained from mitotic cells. They comment on a certain degree of correlation between Pch2 and H3K79me1. However, previous cytological analyses (Ref. 23) go in the opposite direction because Dot1-dependent H3K79 methylation appears to prevent Pch2 mislocalization to euchromatin. That study shows that Pch2 mislocalizes outside the rDNA in dot1 and H3K79 mutants. The authors have opted for not directly analyzing transcription-dependent Pch2 binding in dot1 (and sir2) mutants arguing time restrictions. Although genome-wide ChIP-seq studies could take more time, at least ChIP-qPCR analyses at the same selected target genes explored in other experiments could have been done.

Minor points:

Line 245: Supplementary Figure 3E should be 4E

Line 270: This (delete "is") observation is in agreement...

Lines 390-392 and Supplementary Figure 8G, 8H. Has been the nucleolus included in the quantification of Hop1 "chromosomal" levels? Ref 39 shows that the absence of Pch2 in the nucleolus in orc1 mutants leads to Hop1 mistargeting to the rDNA region. Please, mark the nucleolus in the spread nucleus displayed in Fig S8G to show that Hop1 is mistargeted to the rDNA in orc1-161. The nucleolar area must be eliminated for accurate Hop1 chromosomal quantification.

Line 407: Supplementary Figure 7A-C is erroneously cited here.

Reviewer \#3: Please see attachment

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: None

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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\* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. \*

Dear Gerben,

Thank you very much for submitting your Research Article entitled \'Active transcription and Orc1 drive chromatin association of the AAA+ ATPase Pch2 during meiotic G2/prophase\' to PLOS Genetics, and thank you for the revisions that you made in response to the reviewers\' comments. I am just about ready to proceed with this manuscript, but in reviewing the previous version I slipped up and did not pay attention to the references section, which needs revision to conform to PLOS Genetics style. Unfortunately, because of the way article production works, it is difficult to make substantial changes after a paper has been accepted, and I have been advised in the past that it is better to return the manuscript so that these changes can be made before starting production. I apologize for the inconvenience to you, because I know how much time doing a resubmission can take.

If you will refer to Author instructions (journals.[plos.org/plosgenetics/s/submission-guidelines](http://plos.org/plosgenetics/s/submission-guidelines)), you will find that the recommended format is as follows, in particular using journal abbreviations rather than full journal names:

Hou WR, Hou YL, Wu GF, Song Y, Su XL, Sun B, et al. cDNA, genomic sequence cloning and overexpression of ribosomal protein gene L9 (rpL9) of the giant panda (Ailuropoda melanoleuca). Genet Mol Res. 2011;10: 1576-1588.

Devaraju P, Gulati R, Antony PT, Mithun CB, Negi VS. Susceptibility to SLE in South Indian Tamils may be influenced by genetic selection pressure on TLR2 and TLR9 genes. Mol Immunol. 2014 Nov 22. pii: S0161-5890(14)00313-7. doi: 10.1016/j.molimm.2014.11.005.

Note: A DOI number for the full-text article is acceptable as an alternative to or in addition to traditional volume and page numbers. When providing a DOI, adhere to the format in the example above with both the label and full DOI included at the end of the reference (doi: 10.1016/j.molimm.2014.11.005). Do not provide a shortened DOI or the URL.

Also, if you used Endnote, you can find a link to the appropriate style in the references section of the instructions. Please also make sure that all titles are in sentence case (like this sentence); often when articles are downloaded from journals their titles have Every Word Capitalized and this must be corrected by editing the reference manager entry or the references section. 

Finally, as a matter of genetics style, please make sure that all gene and species names are italicized\--you got it correct for most but I found at least one (ref 50) where it wasn\'t, and may have missed a few others.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

The rest of this letter is boilerplate\--thanks for your interesting article, and I hope to receive the final version soon.

In addition we ask that you:

1\) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2\) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our [archive](http://www.plosgenetics.org/article/browse/volume). If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Michael Lichten, Ph.D.

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics
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Dear Gerben,

We are pleased to inform you that your manuscript entitled \"Active transcription and Orc1 drive chromatin association of the AAA+ ATPase Pch2 during meiotic G2/prophase\" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plosgenetics@plos.org>.

In the meantime, please log into Editorial Manager at <https://www.editorialmanager.com/pgenetics/>, click the \"Update My Information\" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Michael Lichten, Ph.D.

Associate Editor

PLOS Genetics

Gregory P. Copenhaver

Editor-in-Chief

PLOS Genetics

[www.plosgenetics.org](http://www.plosgenetics.org)

Twitter: \@PLOSGenetics

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Comments from the reviewers (if applicable):

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Data Deposition**

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the [Dryad Digital Repository](http://www.datadryad.org). As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our [website](http://journals.plos.org/plosgenetics/s/data-availability#loc-recommended-repositories).

The following link will take you to the Dryad record for your article, so you won\'t have to re‐enter its bibliographic information, and can upload your files directly: 

<http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-19-01662R3>

More information about depositing data in Dryad is available at <http://www.datadryad.org/depositing>. If you experience any difficulties in submitting your data, please contact <help@datadryad.org> for support.

Additionally, please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Press Queries**

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper\'s publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there\'s anything the journal should know or you\'d like more information, please get in touch via <plosgenetics@plos.org>.

10.1371/journal.pgen.1008905.r008
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PGENETICS-D-19-01662R3

Active transcription and Orc1 drive chromatin association of the AAA+ ATPase Pch2 during meiotic G2/prophase

Dear Dr Vader,

We are pleased to inform you that your manuscript entitled \"Active transcription and Orc1 drive chromatin association of the AAA+ ATPase Pch2 during meiotic G2/prophase\" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Jason Norris

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN \| United Kingdom

<plosgenetics@plos.org> \| +44 (0) 1223-442823

[plosgenetics.org](http://plosgenetics.org) \| Twitter: \@PLOSGenetics

[^1]: The authors have declared that no competing interests exist.
